US20220296568A1 - Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof - Google Patents
Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof Download PDFInfo
- Publication number
- US20220296568A1 US20220296568A1 US17/586,354 US202217586354A US2022296568A1 US 20220296568 A1 US20220296568 A1 US 20220296568A1 US 202217586354 A US202217586354 A US 202217586354A US 2022296568 A1 US2022296568 A1 US 2022296568A1
- Authority
- US
- United States
- Prior art keywords
- pamoate
- pramipexole
- ropinirole
- theta
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 160
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title description 17
- 229940125688 antiparkinson agent Drugs 0.000 title 1
- 229960003089 pramipexole Drugs 0.000 claims abstract description 105
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims abstract description 100
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims abstract description 91
- 229960001879 ropinirole Drugs 0.000 claims abstract description 91
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 63
- 229960003179 rotigotine Drugs 0.000 claims abstract description 45
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims abstract description 45
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 230000000648 anti-parkinson Effects 0.000 claims abstract description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 75
- 238000001228 spectrum Methods 0.000 claims description 59
- 239000003937 drug carrier Substances 0.000 claims description 14
- 239000000939 antiparkinson agent Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 abstract description 78
- 238000013265 extended release Methods 0.000 abstract description 25
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 abstract description 9
- 229960000245 rasagiline Drugs 0.000 abstract description 9
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 abstract description 9
- 229950002652 safinamide Drugs 0.000 abstract description 9
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 abstract description 9
- 229960003946 selegiline Drugs 0.000 abstract description 9
- 239000007972 injectable composition Substances 0.000 abstract description 3
- 239000012453 solvate Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 92
- 239000007787 solid Substances 0.000 description 65
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- -1 poly(allylamine hydrochloride) Polymers 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 238000009472 formulation Methods 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- 238000000113 differential scanning calorimetry Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000001757 thermogravimetry curve Methods 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 10
- 238000002441 X-ray diffraction Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 102000010909 Monoamine Oxidase Human genes 0.000 description 7
- 108010062431 Monoamine oxidase Proteins 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940052760 dopamine agonists Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical compound [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- CEXBONHIOKGWNU-NTISSMGPSA-N hydron;(6s)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound [Cl-].CCC[NH+]([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 CEXBONHIOKGWNU-NTISSMGPSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical class C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000002740 Muscle Rigidity Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- SSCNBCJMCHHBPH-GGFXYVROSA-N C#CCN(C)[C@H](C)Cc1ccccc1.C#CCN[C@@H]1CCc2ccccc21.CCCN(CCC)CCc1cccc2c1CC(=O)N2.CCCN[C@H]1CCc2nc(N)sc2C1.C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O.[H][C@]1(N(CCC)CCc2cccs2)CCc2c(O)cccc2C1 Chemical compound C#CCN(C)[C@H](C)Cc1ccccc1.C#CCN[C@@H]1CCc2ccccc21.CCCN(CCC)CCc1cccc2c1CC(=O)N2.CCCN[C@H]1CCc2nc(N)sc2C1.C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O.[H][C@]1(N(CCC)CCc2cccs2)CCc2c(O)cccc2C1 SSCNBCJMCHHBPH-GGFXYVROSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Definitions
- the present invention generally relates to pamoate salts of anti-Parkinson's disease agents, for example, pamoate salts of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and/or safinamide, pharmaceutical compositions comprising such salts, methods of preparing such salts, and methods of treating a subject in need thereof with such salts and compositions.
- pamoate salts of anti-Parkinson's disease agents for example, pamoate salts of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and/or safinamide
- pharmaceutical compositions comprising such salts
- methods of preparing such salts and methods of treating a subject in need thereof with such salts and compositions.
- Parkinson's disease is a motor system disorder of the nervous system. It is characterized as a progressive disorder that affects movement and results in the loss of dopamine-producing brain cells, causing tremor in the hands, arms, legs, jaw, and face and/or rigidity or stiffness of the limbs and trunk.
- the primary symptoms include muscular rigidity, slowness of movement, a resting tremor, and postural instability.
- the most common anti-Parkinson's disease drugs are to either replace the dopamine levels in the brain, mimic the actions of dopamine or slow/inhibit the degradation of dopamine in the brain.
- the main categories of dopaminergic drugs include dopamine agonists such as rotigotine, ropinirole, and pramipexole, of which the chemical structures are depicted below.
- Drugs from the category of monoamine oxidase-B (MAO-B) inhibitors such as selegiline, rasagiline, and safinamide (see chemical structures below) increase the level of dopamine in the basal ganglia by blocking its metabolism. These drugs inhibit MAO-B which breaks down dopamine secreted by the dopaminergic neurons.
- the reduction in MAO-B activity results in increased L-DOPA in the nervous system thus alleviating the symptom from PD.
- the present invention provides a variety of solid state forms, such as pamoate salts of anti-Parkinson's disease agents, e.g., monoamine anti-Parkinson's disease agents (hereinafter “monoamine agent(s)”), in different novel polymorphic forms, and more particularly, pamoate salts of rotigotine, pamoate salts of ropinirole, pamoate salts of pramipexole, pamoate salts of selegiline, pamoate salts of rasagiline, and/or pamoate salts of safinamide.
- pamoate salts of anti-Parkinson's disease agents e.g., monoamine anti-Parkinson's disease agents (hereinafter “monoamine agent(s)”)
- pamoate salts of rotigotine pamoate salts of ropinirole
- pamoate salts of pramipexole pamoate salts of selegi
- the present invention also provides pharmaceutical compositions comprising one or more of such salts, methods of preparing such salts, and methods of treating a subject or patient (such as a human) in need thereof with one or more of such salts and pharmaceutical compositions.
- the present invention also provides formulations comprising one or more of the pamoate salts of the monoamine agents with a long acting and/or extended release profile.
- the monoamine agent can be rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and/or safinamide.
- the monoamine agent can also be ropinirole, pramipexole, or rotigotine.
- the present invention provides novel pamoate salts, e.g., in different polymorphic forms, of monoamine agents.
- the molar ratio of the monoamine agent's free base to pamoic acid is about 1:1 (which is referred to herein as the mono-pamoate salt of the monoamine agent).
- the molar ratio of the monoamine agent's free base to pamoic acid is about 2:1 (which is herein referred as the semi-pamoate salt of the monoamine agent).
- the pamoate salt of the monoamine agent is (1) crystalline, including anhydrous, hydrate, solvate forms and their polymorphs, or (2) amorphous.
- the above salts can be especially useful in preparing a formulation, such as an extended release formulation (or composition) in which the release rate is minimally dependent on the pH of the environment at the injection site.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pamoate salt of a monoamine agent and at least one pharmaceutically acceptable carrier.
- the carrier is a viscous aqueous or nonaqueous carrier.
- the present invention provides a method of preparing a pamoate salt of a monoamine agent comprising treating or mixing the monoamine agent with pamoic acid or treating or mixing a salt of the monoamine agent with a pamoate salt in a solvent.
- the present invention provides a method of treating a subject having syndrome associated with Parkinson's disease comprising administering a therapeutically effective amount of a pamoate salt of a monoamine agent or a pharmaceutical composition comprising a pamoate salt of a monoamine agent and at least one pharmaceutically acceptable carrier to a subject in need of treatment thereof.
- the composition is administered by injection.
- the composition is administered intramuscularly or subcutaneously.
- the present invention provides a formulation (or composition) comprising a pamoate salt of a monoamine agent as an active ingredient or active agent, and one or more pharmaceutically acceptable carriers.
- the formulation (or composition) can meet the unmet need for a stable, pharmaceutically suitable formulation with a controlled and/or sustained release rate which can be useful as a depot formulation or for intramuscular or subcutaneous use.
- FIG. 1 depicts an X-ray powder diffraction (“XRPD”) spectrum of ropinirole pamoate Form A (1:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of DMSO and water.
- XRPD X-ray powder diffraction
- FIG. 2 depicts a differential scanning calorimetry (“DSC”) thermogram of ropinirole pamoate Form A (1:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture DMSO and water.
- DSC differential scanning calorimetry
- FIG. 3 depicts an XRPD spectrum of ropinirole pamoate Form B (1:1 molar ratio of ropinirole to pamoic acid) obtained from heating materials depicted in FIGS. 1 and 2 at 170° C. for 30 minutes.
- FIG. 4 depicts a DSC thermogram of ropinirole pamoate Form B (1:1 molar ratio of ropinirole to pamoic acid) obtained from heating materials depicted in FIGS. 1 and 2 at 170° C. for 30 minutes.
- FIG. 5 depicts an XRPD spectrum of ropinirole pamoate Form C (2:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of ethanol, water and PEG6000.
- FIG. 6 depicts a DSC thermogram of ropinirole pamoate Form C (2:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of ethanol, water and PEG6000.
- FIG. 7 depicts an XRPD spectrum of ropinirole pamoate Form D (1:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of DMSO and acetonitrile.
- FIG. 8 depicts a DSC thermogram of ropinirole pamoate Form D (1:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of DMSO and acetonitrile.
- FIG. 9 depicts an XRPD spectrum of ropinirole pamoate Form E (2:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of ethanol, water and poly(allylamine hydrochloride).
- FIG. 10 depicts a DSC thermogram of ropinirole pamoate Form E (2:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of ethanol, water and poly(allylamine hydrochloride).
- FIG. 11 depicts an XRPD spectrum of rotigotine pamoate Form I (1:1 molar ratio of rotigotine to pamoic acid) obtained from a mixture of ethanol, acetone, and n-heptane.
- FIG. 12 depicts a DSC thermogram of rotigotine pamoate Form I (1:1 molar ratio of rotigotine to pamoic acid) obtained from a mixture of ethanol, acetone, and n-heptane.
- FIG. 13 depicts an XRPD spectrum of pramipexole pamoate Form 1 (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and water.
- FIG. 14 depicts a DSC thermogram of pramipexole pamoate Form 1 (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and water.
- FIG. 15 depicts an XRPD spectrum of pramipexole pamoate Form 2 (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and methanol.
- FIG. 16 depicts a DSC thermogram of pramipexole pamoate Form 2 (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and methanol.
- FIG. 17 depicts an XRPD spectrum of pramipexole pamoate Form 3 (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of ethyl acetate.
- FIG. 18 depicts a DSC thermogram of pramipexole pamoate Form 3 (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of ethyl acetate.
- FIG. 19 depicts an XRPD spectrum of pramipexole pamoate Form 4 (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of tetrahydrofuran.
- FIG. 20 depicts a DSC thermogram of pramipexole pamoate Form 4 (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of tetrahydrofuran.
- FIG. 21 depicts a 1 H-NMIR spectrum of pramipexole pamoate (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and water.
- FIG. 22 depicts a 1 H-NMIR spectrum of pramipexole pamoate (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of tetrahydrofuran.
- FIG. 23 depicts a 1 H-NMIR spectrum of Ropinirole pamoate (1:1 molar ratio of Ropinirole to pamoic acid) obtained from Example 1.
- FIG. 24 depicts a 1 H-NMIR spectrum of Ropinirole pamoate (2:1 molar ratio of Ropinirole to pamoic acid) obtained from Example 3.
- FIG. 25 depicts a 1 H-NMR spectrum of Rotigotine pamoate (1:1 molar ratio of Rotigotine to Pamoic acid) obtained from Example 6.
- FIG. 26 depicts a 1 H-NMIR spectrum of pramipexole pamoate (2:1 molar ratio of pramipexole to pamoic acid) obtained from Example 9.
- any numerical value recited herein includes all values from the lower value to the upper value, i.e., all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in the present application.
- Monoamine anti-PD agents are weak organic bases. In an alkaline solution (high pH), they exist as the free base form. Aqueous solubility of the monoamine agents increase with decreasing pH of the solution due to an increasing fraction of the drug being ionized. At high concentrations of the ionized drug (protonated amine), the salt form will precipitate out due to exceeding solubility product (K sp ). The nature of the drug and counter-ion determine the K sp and the associated solid state properties of the salt.
- hydrochloride form There are a wide range of counter-ions to prepare salts of bases using inorganic and organic acids.
- the most frequently used anions to form a salt of a basic drug is the hydrochloride form.
- Requip XL an extended-release tablet and a commercial product of dopamine agonist ropinirole for oral administration, is a hydrochloride salt.
- Transdermal patch of ropinirole also use its hydrochloride salt as active pharmaceutical ingredient (API) (U.S. Pat. No. 5,807,570 by Chen et al.).
- API active pharmaceutical ingredient
- pramipexole dihydrochloride monohydrate was dispersed in a matrix comprising a hydrophilic polymer to achieve 24 hours release (US patent Nos.
- the present inventor has discovered that it is desirable to formulate the monoamine agents, e.g., in a depot formulation or as an injectable formulation such as an intramuscular or subcutaneous formulation, to assure consistent and proper dosage of the drug substance and to maximize the clinical benefits through maintaining a sustained and continuous drug concentration and improve patient compliance.
- pH of muscle tissue can fluctuate with exercise, stress, and injury which may impact drug solubility, and thus the rate of absorption of injectable drugs. Therefore, in some embodiments, it is also desirable to develop an injectable extended release formulation in which the release rate of the active ingredient is minimally dependent on pH fluctuation, such as those related to exercise, stress, and/or injury.
- the present inventor has found that a solid state or solid forms of anti-Parkinson's disease agents such as a monoamine anti-Parkinson's disease (anti-PD) agent pamoate salt, can be advantageous.
- pamoate salts of the monoamine agents with specific polymorphic form and particle size distribution in a suitable formulation can provide a desired long acting and/or extended release profile.
- Such pamoate salts of the monoamine agent can provide an alternative and more desirable dosing regimen for treatment of patients suffering from Parkinson's disease (PD). It will also have superior drug absorption and distribution profiles compared to the existing oral drug products by providing a continuous delivery of drug, which would maintain stable plasma drug levels and reduce maximum to minimum plasma drug concentration ratio during dosing intervals, thus, ultimately improve safety profile and enhance clinical effectiveness.
- pamoic acid The chemical structure of pamoic acid is:
- the molecular weight of pamoic acid is 388 g/mol, the pK a1 is 2.51, and pK a2 is 3.1.
- both carboxylic counter ions can form salt with the amine of the monoamine agents, resulting in a molar ratio of the monoamine agents to pamoic acid of about 1:1 or about 2:1, such as those specified in FIGS. 1-20 .
- the invention provides pamoate salts of anti-PD agents such as monoamine anti-PD agents and compositions and formulations containing said pamoate salts.
- the pamoate salt is characterized by a molar ratio of the monoamine agent to pamoic acid of about 1:1 or about 2:1.
- the pamoate salt can be crystalline, anhydrous, hydrated, solvated, or amorphous.
- the invention provides pamoate salt of ropinirole, e.g., five crystalline Forms, Form A to Form E, of pamoate salt of ropinirole.
- Forms A, B, and D of pamoate salt of ropinirole each has a molar ratio of ropinirole to pamoic acid of about 1:1
- Forms C and E of pamoate salt of ropinirole each has a molar ratio of ropinirole to pamoic acid of about 2:1.
- Pamoate salts of ropinirole can be prepared by those skilled in the art in view of the present disclosure, see e.g., the Examples section.
- Forms A, B, C, D, E of pamoate salt of ropinirole can be prepared by following the procedures described in Examples 1-5 in the Examples section, respectively.
- the crystalline Form A to Form E of pamoate salt of ropinirole can be characterized by one or more of the following properties: (1) an X-ray powder diffraction pattern having peak(s) expressed as 2-theta from 3 to 40 degrees substantially in accordance with (e.g., within ⁇ 0.2° 2-theta) one or more (e.g., two or more, three or more, etc., e.g., 1, 2, 3, 4, 5, 6, or more) of the main peaks shown in FIGS. 1, 3, 5, 7, 9 , respectively, for each crystalline form; (2) an X-ray powder diffraction pattern substantially in accordance with those shown in FIGS.
- main peaks refer to peaks in an MOD spectrum (e.g., as shown in the FIGs and Tables herein) that have a relative intensity (height) of about 15% or more, preferably, about 30% or more (e.g., 35% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more).
- main peaks refers to peaks in an XRPD spectrum (e.g., as shown in the FIGs and Tables herein) that have a relative intensity (height) of about 80% or more.
- ropinirole pamoate in crystalline Form A can be characterized by an XRPD spectrum having one or more (e.g., 4 or more, 6 or more, 8 or more, 10 or more, 12 or more, or all of) of the following peaks: 4.3, 9.8, 11.5, 14.4, 16.0, 17.1, 18.6, 19.1, 20.5, 21.0, 23.1, 23.8, 26.5, and 26.9, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form A can be characterized by an XRPD spectrum having one or more (e.g., 2 or more, 4 or more, 6 or more, or all of) of the following peaks: 4.3, 9.8, 17.1, 18.6, 19.1, 20.5, 21.0, and 23.1, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form A can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 4.3, 17.1, 18.6, and 20.5, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form B can be characterized by an XRPD spectrum having one or more (e.g., 4 or more, 6 or more, 8 or more, 10 or more, or all of) of the following peaks: 9.4, 11.5, 12.0, 12.7, 15.6, 16.4, 17.2, 18.7, 21.0, 23.1, 23.4, and 26.2, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form B can be characterized by an XRPD spectrum having one or more (e.g., 2 or more, 4 or more, 6 or more, or all of) of the following peaks: 11.5, 12.0, 12.7, 16.4, 21.0, 23.1, 23.4, and 26.2, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form B can be characterized by an XRPD spectrum having one or more (e.g., 2 or more, 4 or more, or all of) of the following peaks: 11.5, 16.4, 21.0, 23.1, 23.4, and 26.2, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form C can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 8.0, 9.5, 16.1, and 18.8, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form C can be characterized by an XRPD spectrum having peaks at 16.1 and 18.8, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form D can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, or 6) of the following peaks: 14.3, 17.9, 21.5, 22.4, 24.8, and 25.2, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form D can be characterized by an XRPD spectrum having one or more (1, 2, or 3) of the following peaks: 14.3, 17.9, and 25.2, ⁇ 0.2° 2-theta, for example, ropinirole pamoate in crystalline Form D can be characterized by an XRPD spectrum having a peak at 17.9 ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form E can be characterized by an XRPD spectrum having one or more (e.g., 4 or more, 6 or more, 8 or more, 10 or more, or all of) of the following peaks: 11.1, 11.7, 12.0, 15.5, 18.8, 19.6, 20.2, 21.0, 22.9, 23.6, 26.1, and 26.6, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form E can be characterized by an XRPD spectrum having one or more (e.g., 2 or more, 4 or more, or all of) of the following peaks: 11.1, 11.7, 12.0, 21.0, 26.1, and 26.6, ⁇ 0.2° 2-theta.
- ropinirole pamoate in crystalline Form E can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, or 3) of the following peaks: 11.7, 12.0, and 21.0, ⁇ 0.2° 2-theta.
- each of the crystalline Form A to Form E of pamoate salts of ropinirole can be substantially pure, for example, each form can be substantially free of other crystalline or amorphous forms of pamoate salts of ropinirole (e.g., less than 20%, less than 10%, less than 5%, or not detectable with the XRPD method described herein).
- each of the crystalline Form A to Form E of pamoate salts of ropinirole can exist in a mixture with one or more other forms of pamoate salts of ropinirole, crystalline or amorphous.
- the invention relates to pamoate salt of rotigotine, e.g., crystalline Form I of pamoate salt of rotigotine, which has a molar ratio of rotigotine to pamoic acid of about 1:1.
- pamoate salts of rotigotine can be prepared by those skilled in the art in view of the present disclosure, see e.g., the Examples section.
- Form I of pamoate salt of rotigotine can be prepared by following the procedures described in Example 6 in the Examples section.
- the crystalline Form I of pamoate salt of rotigotine can be characterized by one or more of the following properties: (1) an X-ray powder diffraction pattern having peak(s) expressed as 2-theta from 3 to 40 degrees substantially in accordance (e.g., within ⁇ 0.2° 2-theta) one or more (e.g., two or more, three or more, etc., e.g., 1, 2, 3, 4, 5, 6, or more) of with the main peaks shown in FIG. 11 ; (2) an X-ray powder diffraction pattern substantially in accordance with that shown in FIG. 11 ; (3) a differential scanning calorimetry thermogram pattern substantially in accordance with that shown in FIGS.
- Form I of pamoate salt of rotigotine can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) of the following peaks: 4.6, 9.3, 17.5, 18.7, 24.2, 26.4, 28.2, and 29.6, ⁇ 0.2° 2-theta.
- Form I of pamoate salt of rotigotine can be characterized by an XRPD spectrum having one or both peaks at 4.6 and 9.3, ⁇ 0.2° 2-theta.
- the crystalline Form I of pamoate salt of rotigotine can be substantially pure, for example, substantially free of other crystalline or amorphous forms of pamoate salt of rotigotine (e.g., less than 20%, less than 10%, less than 5%, or not detectable with the XRPD method described herein).
- the crystalline Form I of pamoate salt of rotigotine can exist in a mixture with one or more other forms of pamoate salt of rotigotine, crystalline or amorphous.
- the invention relates to pamoate salt of pramipexole, e.g., crystalline forms, Form 1 to Form 4, of pamoate salt of pramipexole.
- Pamoate salts of pramipexole can be prepared by those skilled in the art in view of the present disclosure, see e.g., the Examples section.
- Forms 1-4 of pamoate salt of pramipexole can be prepared by following the procedures described in Examples 7-10 in the Examples section, respectively.
- Forms 1 and 2 of pamoate salt of pramipexole each has a molar ratio of pramipexole to pamoic acid of about 1:1
- Forms 3 and 4 of pamoate salt of pramipexole each has a molar ratio of pramipexole to pamoic acid of about 2:1.
- the crystalline Form 1 to Form 4 of pamoate salt of pramipexole can be characterized by one or more of the following properties: (1) an X-ray powder diffraction pattern having peak(s) expressed as 2-theta from 3 to 40 degrees substantially in accordance with (e.g., within ⁇ 0.2° 2-theta) one or more (e.g., two or more, three or more, etc., e.g., 1, 2, 3, 4, 5, 6, or more) of the main peaks shown in FIG. 13, 15, 17, 19 , respectively, for each crystalline form; (2) an X-ray powder diffraction pattern substantially in accordance with those shown in FIG. 13, 15, 17, 19 , respectively, for each crystalline form; (3) a differential scanning calorimetry thermogram pattern substantially in accordance with those shown in FIG. 14, 16, 18, 20 , respectively for each crystalline form; and (4) any combinations of (1), (2) and (3).
- Form 1 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9) of the following peaks: 7.7, 11.8, 13.8, 15.3, 18.9, 21.1, 23.1, 23.7, and 26.4, ⁇ 0.2° 2-theta.
- Form 1 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, or 3) of the following peaks: 13.8, 15.3, and 21.1, ⁇ 0.2° 2-theta.
- Form 2 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) of the following peaks: 12.0, 15.0, 17.2, 20.4, 20.9, 22.5, 23.3, and 25.4, ⁇ 0.2° 2-theta.
- Form 2 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, or 6) of the following peaks: 12.0, 15.0, 20.4, 20.9, 22.5, and 23.3, ⁇ 0.2° 2-theta.
- Form 2 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 12.0, 15.0, 20.4, and 20.9, ⁇ 0.2° 2-theta.
- Form 3 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) of the following peaks: 10.7, 12.7, 13.5, 14.9, 16.3, 18.1, 18.7, and 22.3, ⁇ 0.2° 2-theta.
- Form 3 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, or 6) of the following peaks: 10.7, 12.7, 13.5, 14.9, 18.7, and 22.3, ⁇ 0.2° 2-theta.
- Form 3 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 10.7, 12.7, 13.5, and 14.9, ⁇ 0.2° 2-theta.
- Form 4 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of the following peaks: 6.1, 13.5, 14.9, 17.9, 18.9, 21.3, 21.8, 22.4, 23.2, and 24.0, ⁇ 0.2° 2-theta.
- Form 4 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, or 6) of the following peaks: 6.1, 17.9, 18.9, 21.3, 23.2, and 24.0, ⁇ 0.2° 2-theta.
- Form 4 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 6.1, 17.9, 21.3, and 23.2, ⁇ 0.2° 2-theta.
- Form 4 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having the following peaks: 6.1 and 17.9, ⁇ 0.2° 2-theta.
- each of the crystalline Form 1 to Form 4 of pamoate salt of pramipexole can be substantially pure, for example, each form can be substantially free of other crystalline or amorphous forms of pamoate salt of pramipexole (e.g., less than 20%, less than 10%, less than 5%, or not detectable with the XRPD method described herein).
- each of the crystalline Form 1 to Form 4 of pamoate salt of pramipexole can exist in a mixture with one or more other forms of pamoate salt of pramipexole, crystalline or amorphous.
- the invention further provides a pharmaceutical composition comprising one or more of the pamoate salts of the monoamine anti-PD agents (e.g., any of those described herein, e.g., Forms A-E of pamoate salt of ropinirole, Form I of pamoate salt of rotigotine, Forms 1-4 of pamoate salt of pramipexole) and at least one pharmaceutically acceptable carrier.
- the pharmaceutical composition is an intramuscularly or subcutaneously injectable formulation.
- the pharmaceutical composition is an extended release formulation comprising pamoate salts of the monoamine agents and a polymer (e.g., a release control polymer).
- Polymers suitable for use in the extended release formulations include any of those known in the art. Some of which can be found, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co.
- the extended release can be based on the slow dissolution rate of the pamoate salts herein.
- the extended release formulation can also be free or substantially free of a polymer, for example, the extended release formulation can be free or substantially free a release control polymer.
- the pharmaceutically acceptable carrier is a viscous aqueous or nonaqueous fluid.
- the viscous aqueous or nonaqueous fluid can have a viscosity of at least 20 cp at 20° C.
- the viscous aqueous or nonaqueous fluid can have a viscosity at 20° C. of at least about 30 cp, e.g., about 40 cp, about 50 cp, about 60 cp, at least about 40 cp, at least about 50 cp, or at least about 60 cp.
- the pharmaceutical composition releases an effective amount of the active agent (one or more of the pamoate salts of the monoamine agents as described herein) over a period of at least about 24 hours or at least about 48 hours.
- the active agent in the pharmaceutical composition has a duration of efficacy of at least about 7 days or at least about 14 days.
- the invention further relates to methods of treating a subject having syndrome associated with Parkinson's disease, such as a warm blood mammal (such as a human patient or subject characterized as having Parkinson's disease).
- the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a pamoate salt of the monoamine agent (e.g., any of those described herein) and at least one pharmaceutically acceptable carrier.
- the present inventor discovered that the pharmaceutically acceptable salts of the monoamine agents formed using pamoic acid as a counterion surprisingly exhibit very low solubility (K T ). This low solubility can be highly desirable when used in a pharmaceutical composition to provide for extended release of the pamoate salt of the monoamine agents, for example, when administered intramuscularly or subcutaneously.
- the pharmaceutical compositions of the present invention include various pharmaceutical dosage forms for the purposes of administering dosage to a subject (such as a warm blooded mammal, such as a human) in need of treatment of Parkinson's disease.
- a pharmaceutically effective amount of one or more pamoate salts of the monoamine agent (as the active ingredient or active agent) are combined with one or more pharmaceutically acceptable excipients.
- the pharmaceutically acceptable excipients used are generally less critical, are well known in the art, and may take a wide variety of forms depending on the form of preparation desired for administration. In some embodiments, these pharmaceutical compositions are provided in a unit dosage form suitable for administration.
- compositions of the present invention can be, for example, parenterally, such as by subcutaneous or intramuscular injection or implantation.
- the pamoate salts of the monoamine agents can be, for example, suspended in an aqueous solvent, which can further comprise a wetting agent, such as the polyoxyethylene derivatives of sorbitan esters, e.g. polysorbate 80 (Tween® 80) and polysorbate 20 (Tween® 20), lecithin, polyoxyethylene- and polyoxypropylene ethers, sodium deoxycholate, and the like; a suspending agent such as a cellulose derivate, e.g.
- the pamoate salts of the monoamine agents can also be formulated in one or more oils.
- oils that can be used include fixed oils, for example, peanut oil, sesame oil, cottonseed oil, corn oil, safflower oil, castor oil, ethyloleate, soybean oil, synthetic glycerol esters of long chain fatty or medium chain acids and mixtures of these and other oils.
- thickening agents can be added to the composition, e.g. aluminum monostearate, ethylcellulose, triglycerides, hydrogenated castor oil, and the like.
- the present invention further provides a method of treating warm-blooded mammals (such as humans), suffering from PD.
- the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising at least one pamoate salt of the monoamine agents as described herein and one or more pharmaceutically acceptable excipients.
- the pharmaceutical compositions described herein can be administered to a subject in need of treatment of Parkinson's disease as a long acting composition.
- the active agent is released from the composition over a period of at least about 24 hours, preferably at least about 48 hours.
- the active agent can also be administered in an extended release composition.
- the extended release composition releases the active agent over a period of at least about 7 days, preferably at least about 14 days, alternatively for at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 6 weeks or at least 8 weeks.
- the composition can be administered by injection, such as intramuscularly or subcutaneously.
- the compositions can be administered as a single or sole dose.
- the compositions described herein are particularly beneficial for those subjects in need of treatment of Parkinson's disease that require constant or chronic therapy, such as those subjects that receive repeated doses over several weeks or months or more.
- the method can comprise: (1) administering as first dose an first extended release composition containing one or more of the pamoate salts of the monoamine agents as described herein followed by (2) administering as a second dose (and as subsequence doses if necessary), a second extended release composition.
- the second extended release composition can be the same, substantially the same or different than the first extended release composition.
- the second extended release composition can include as the active agent of one or more of the pamoate salts of the monoamine agents as described herein or an active agent that is other than the pamoate salts of the monoamine agents as described herein.
- the second composition can be administered at about 7 days, or more, such as at least about 14 days, or at least about 21 days, after the first administration of the first extended release composition, where the first administration results in the release of active agent for a period of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or more.
- the term “about” modifying an amount related to the invention refers to variation in the numerical quantity that can occur, for example, through routine testing and handling; through inadvertent error in such testing and handling; through differences in the manufacture, source, or purity of ingredients employed in the invention; and the like.
- “about” a specific value also includes the specific value, for example, about 10% includes 10%. Whether or not modified by the term “about”, the claims include equivalents of the recited quantities. In one embodiment, the term “about” means within 20% of the reported numerical value.
- the term “individual”, “subject” or “patient” refers to a warm blooded animal which is afflicted with a particular disease state.
- Warm blooded animals include mammals, such as humans.
- an effective amount or “therapeutically effective amount” is defined as an amount resulting in the improvement of any parameters or clinical symptoms.
- the term “effective amount” or “therapeutically effective amount” can be an amount resulting in the improvement of any parameters or clinical symptoms associated with Parkinson's disease.
- the actual dose may vary with each patient and does not necessarily indicate a total elimination of all disease symptoms.
- a therapeutically effective amount of the compound used in the methods described herein can be readily determined by one skilled in the art, such as an attending physician, by observing results obtained under analogous circumstances and by using conventional techniques.
- the attending physician considers a number of factors, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
- the term “duration of efficacy” or “therapeutically effective plasma concentration” of a monoamine for a given time period should be understood as such that during such time period, the respective monoamine is present (e.g., in the plasma of a subject treated with the pamoate salt herein) in an amount and/or concentration sufficient to result in the improvement of any parameters or clinical symptoms, for example, the improvement of any parameters or clinical symptoms associated with Parkinson's disease.
- Preferred amounts and modes of administration can be readily be determined by one skilled in the art depending upon the particular characteristics of the compound selected, the disease state to be treated, the stage of the disease, and other relevant circumstances using formulation technology known in the art, described for example in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co.
- compositions can be manufactured utilizing routine techniques known in the art. Typically a therapeutically effective amount of the compound (salt) will be combined with a pharmaceutically acceptable carrier.
- compositions of the present invention can be administered parenterally.
- they can be administered by injection.
- Preferred methods of parenteral administration include intramuscular and subcutaneous injection.
- the compounds (salt) can be dissolved in a physiologically acceptable pharmaceutical carrier and administered as either a solution or a suspension.
- Viscous injectable carriers are preferred, having for example, a viscosity of at least 20 cp at 20° C.
- the fluid phase of the suspension has a viscosity at 20° C. of at least about 30 cp, e.g., about 40 cp, about 50 cp, about 60 cp, at least about 40 cp, at least about 50 cp, or at least about 60 cp.
- the composition can also comprise a viscosity enhancing agent, a density enhancing agent, a tonicity enhancing agent, and/or a wetting agent.
- Suitable pharmaceutical carriers include water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative, or synthetic origin.
- the pharmaceutical carrier may also contain preservatives, and buffers as known in the art.
- composition When the composition is to be used as an injectable material, including, but not limited to, needle-less injection, it can be formulated into a conventional injectable carrier.
- Suitable carriers include biocompatible and pharmaceutically acceptable solutions, emulsions or suspensions.
- the formulation can be surgically implanted.
- Such formulations can include any of the well-known biodegradable and bioerodible carriers, such as polylactides, poly-lactide-co-glycolides and collagen formulations.
- Such materials can be in the form of solid implants, sponges, and the like.
- the active ingredients usually are present in the carrier or excipient in a weight ratio of from about 1:1000 to 1:20,000, but are not limited to ratios within this range.
- pamoate salts of the monoamine agents can be prepared in a variety of different ways.
- pamoate salts of the monoamine agents can be prepared directly by treating or mixing the monoamine agents (such as a free base) with pamoic acid in a solvent (such as water, ethanol or DMSO).
- pamoate salts of the monoamine agents can be prepared by treating or mixing the monoamine agents salt (such as a hydrochloride salt) with a pamoate salt (such as disodium pamoate) in one or more solvents.
- the pamoate of the monoamine agents can be prepared by adding a solution of disodium pamoate, or other pamoate salt in an appropriate solvent, such as water, to a solution of the monoamine agent hydrochloride and leaving the solution to stir for a period of time, such as, for example, about 3 or 12 hours, until precipitation occurs.
- solvents useful for preparing the pamoate salts herein include, without limitation, water, alkanols (e.g. methanol and ethanol), alkyl ketones (e.g. acetone), alkanes (e.g.
- n-heptane acetonitrile
- toluene DMSO
- alkyl ester e.g. ethyl acetate
- halogenated alkanes e.g. chloroform
- ethers tetrahydrofuran (THF), 1,4-dioxane, and combinations thereof.
- the present invention provides a solid state form of pharmaceutical acceptable salt of dopamine agonists rotigotine, ropinirole, and pramipexole, wherein the salt is a pamoate salt.
- the pamoate salt can be crystalline, anhydrous, hydrated, solvated, or amorphous.
- the invention relates to crystalline pamoate salts of rotigotine, ropinirole, or pramipexole having or characterized by one or more of the following properties: (1) an X-ray powder diffraction pattern substantially in accordance with those shown in FIGS.
- the present invention also relates to compositions containing one or more of the above described pamoate salts of rotigotine, ropinirole, and pramipexole and pharmaceutical compositions containing said compositions and at least one pharmaceutically acceptable carrier.
- the present invention provides a solid state form of a pharmaceutical acceptable salt of anti-PD MAO-B inhibitors selegiline, rasagiline, and safinamide, wherein the salt is a pamoate salt.
- the pamoate salt can be crystalline, anhydrous, hydrated, solvated, or amorphous.
- the present invention also provides compositions containing one or more of the above described pamoate salts of selegiline, rasagiline, and safinamide and pharmaceutical compositions containing said compositions and at least one pharmaceutically acceptable carrier.
- Ropinirole (2 g, 7.7 mmol) and Pamoic Acid (2.975 g, 7.7 mmol) was added into DMSO (15 mL) with stirring to form a solution.
- the resultant solution was slowly added to water (500 mL) at room temperature which produced a white solid.
- the solid was collected on a filter, washed with water, and dried in vacuum at 40° C. to generate Ropinirole Pamoate as white solids (4.0 g, 80.4%).
- X-ray powder diffraction (“XRPD”) patterns of above solids were obtained using a Bruker D8 Advance x-ray powder diffractometer with copper K ⁇ radiation at a wavelength of 1.54 nm. Instrumental conditions included a step size of 0.02 degree per step, a scan rate of 0.2 seconds per step, a 2-theta range of 3 to 40 degrees, a voltage of 40 kV, a current of 40 mA, and a Lynxeye detector. Samples were packed into recessed sample holders for analysis. Typically, the error margin for 2-theta values is ⁇ 0.2°. XRPD patterns for other examples herein were obtained similarly. A typical example of X-ray powder diffraction pattern and data, respectively, for the salt from Example 1 is shown in FIG. 1 and Table 1 wherein d(A) represents the interplanar spacing. Height and Height % represent the typical relative intensities.
- the differential scanning calorimetry thermogram of above solids was obtained using a TA Instrument Q200 Differential Scanning calorimeter. The measurement was controlled by “Thermal Advantage” system and data was analyzed using “Universal Analysis” software. Typical sample load ranges from 0.5 to 5 mg. The measurement is under an atmosphere of nitrogen with flow rate of 40 mL/min. System equilibrium is set at 20° C. and the temperature is then increased to 250° C. at a rate of 10° C./min. Typically, the error margin for DSC peak values is ⁇ 3° C. DSC thermograms for other examples herein were obtained similarly. A typical example of a differential scanning calorimetry thermogram for the salt from Example 1 is shown in FIG. 2 . 1 H NMR (see FIG. 23 ) indicates that the molar ratio of Ropinirole to Pamoic Acid in the salt from Example 1 is about 1:1.
- ropinirole pamoate from Example 1 100 mg was dissolved in 0.45 mL of dimethyl sulfoxide (DMSO). To the solution at room temperature was added 5 mL of acetonitrile. The resultant solution was then stirred at 4° C. to yield a solid, which was collected, washed, and dried. A typical example of an X-ray diffraction pattern for this solid is shown in FIG. 7 and Table 4. A typical example of a differential scanning calorimetry thermogram for this solid is shown in FIG. 8 . 1 H NMR indicates that the molar ratio of Ropinirole to Pamoic Acid in this solid is about 1:1.
- DMSO dimethyl sulfoxide
- ropinirole pamoate from Example 1 100 mg was dissolved in a mixture of 14 mL of ethanol and 7 mL of water. To the solution was added 10% poly(allylamine hydrochloride). After kept evaporation at 40° C., a solid was formed and characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in FIG. 9 and Table 5. A typical example of a differential scanning calorimetry thermogram for this solid is shown in FIG. 10 . 1 H NMR indicates that the molar ratio of Ropinirole to Pamoic Acid in this solid is about 2:1.
- FIG. 11 A typical example of an X-ray diffraction pattern for this solid is shown in FIG. 11 and Table 6.
- a typical example of a differential scanning calorimetry thermogram for this solid is shown in FIG. 12 .
- 1 H NMR indicates that the molar ratio of Rotigotine to Pamoic acid in this solid is about 1:1.
- Pramipexole (3.0 g, 14.1 mmol) and Pamoic acid (2.7 g, 7.0 mmol) was dissolved by stirring at room temperature in DMSO (30 mL). The solution was then slowly added to ethyl acetate (2 L) at room temperature to generate a white solid. The solid was collected on a filter and dried in vacuum at 45° C. to give an amorphous pramipexole pamoate at a 2:1 Molar ratio of Pramipexole to Pamoic acid (4.5 g, 78.6%).
- amorphous pramipexole pamoate salt from Example 7 was dissolved in 0.6 mL of methanol at room temperature. To the solution was added 3 mL of acetone with stirring to yield pramipexole pamoate as a crystalline solid, which was collected, washed, and dried. The solid was characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in FIG. 15 and Table 8. A typical example of a differential scanning calorimetry thermogram for this solid is shown in FIG. 16 . 1 H NMR indicates that the molar ratio of Pramipexole to Pamoic acid in this solid is about 1:1.
- amorphous pramipexole pamoate salt from Example 7 was dissolved in 2.5 mL of ethyl acetate. The solution was stirred for 5 days at room temperature to yield pramipexole pamoate as a solid, which was collected, washed, and dried.
- the solid was characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in FIG. 17 and Table 9. A typical example of a differential scanning calorimetry thermogram for this solid is shown in FIG. 18 . 1 H NMR (see FIG. 26 ) indicates that the molar ratio of Pramipexole to Pamoic acid in this solid is about 2:1.
- amorphous pramipexole pamoate salt from Example 7 was dissolved in 2.5 mL of tetrahydrofuran (THF). The solution was stirred for 10 days at room temperature to yield pramipexole pamoate as a solid, which was collected, washed, and dried.
- the solid was characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in FIG. 19 and Table 10. A typical example of a differential scanning calorimetry thermogram for this solid is shown in FIG. 20 . 1 H NMR (see FIG. 22 ) indicates that the molar ratio of Pramipexole to Pamoic acid in this solid is about 2:1.
- FIGS. 21 and 22 Pramipexole pamoates (1:1 and 2:1) were analyzed using 1 H-NMR.
- the 1 H-NMR spectra are provided in FIGS. 21 and 22 .
- FIG. 21 is the 1 H-NMR spectrum of the 1:1 salt prepared from a mixture of acetone and water (Example 7).
- the molar ratio of pramiperxol to pamoic acid was approximately 1:1 measured from proton integration of the 1 H NMR spectrum.
- FIG. 22 is the 1 H-NMR spectrum of the 2:1 salt prepared in a solution of tetrahydrofuran (Example 10).
- the molar ratio of pramipexole to pamoic acid was approximately 2:1 measured from proton integration of the 1 H-NMR spectrum.
- 1 H-NMR 500 MHz, DMSO-d 6 ) chemical shifts were recorded at (in ppm) 8.65 (b, 2H), 8.19 (m, 2H), 7.63 (d, 1H), 7.11 (m, 1H), 6.99 (m, 1H), 6.78 (s, 2H), 4.67 (s, 1H), 3.59 (m, 2H), 3.49 (m, 1H), 2.97 (m, 3H), 2.50-2.68 (m, 3H), 2.17 (m, 1H), 1.51-1.83 (m, 5H), 1.65 (m, 2H), 0.95 (t, 3H).
- This example provides a crystalline form screening summary of the pramipexole pamoate salt described in the above examples.
- the solvent used to prepare the crystalline form of pramipexole pamoate can be important as many solvents or solvent system did not work for the formation of crystalline salt form.
- a panel of solvents or the combination of these solvents including water, alkanols (e.g. methanol and ethanol), alkyl ketones (e.g. acetone), alkanes (e.g. n-heptane), acetonitrile, toluene, DMSO, alkyl ester (e.g. ethyl acetate), halogenated alkanes (e.g. chloroform), THF, and 1,4-dioxane were screened to generate the crystalline form of the pramipexole pamoate salt.
- alkanols e.g. methanol and ethanol
- alkyl ketones e.g. acetone
- alkanes e.g. n-heptane
- acetonitrile acetonitrile
- toluene DMSO
- alkyl ester e.g. ethyl acetate
- Example 7 Between two crystalline forms of mono-pramipexole pamoate salt obtained using the above solvent systems, the form that was obtained from acetone and water in Example 7 is more stable.
- the form from Example 8 started converting into the crystalline form depicted in Example 7 upon standing at room temperature after 7 days.
- the form described in Example 10 was more stable.
- the crystalline form of semi-pramipexole pamoate salt from Example 9 was converting into amorphous state when placed in the dry box at room temperature.
- Ropinirole (1.3 g, 5 mmol) and Pamoic Acid (0.967 g, 2.5 mmol) was added into DMSO (8 mL) with stirring to form a solution.
- the resultant solution was slowly added to water (250 mL) at room temperature which produced a white solid.
- the solid was collected on a filter, washed with water, and dried in vacuum at 45° C. to generate Ropinirole Pamoate as white solids (2.1 g, 92.6%).
- Rotigotine (3 g, 9.51 mmol) and Pamoic Acid (3.68 g, 9.51 mmol) was added into DMSO (40 mL) with stirring to form a solution.
- the resultant solution was slowly added to water (500 mL) at room temperature which produced a white solid.
- the solid was collected on a filter, washed with water, and dried in vacuum at 45° C. to generate Rotigotine Pamoate as white solids (5 g, 74.9%).
- Rotigotine (1 g, 3.17 mmol) and Pamoic Acid (0.614 g, 1.585 mmol) was added into DMSO (8 mL) with stirring to form a solution.
- the resultant solution was slowly added to water (500 mL) at room temperature which produced a white solid.
- the solid was collected on a filter, washed with water, and dried in vacuum at 45° C. to generate Rotigotine Pamoate as white solids (2 g, 77.4%).
- Pramipexole (5.0 g, 23.44 mmol) and Pamoic acid (9.08 g, 23.44 mmol) was dissolved by stirring at room temperature in DMSO (50 mL). The solution was then slowly added to ethyl acetate (2 L) at room temperature to generate a white solid. The solid was collected on a filter and dried in vacuum at 45° C. to give pramipexole pamoate at a 1:1 Molar ratio of Pramipexole to Pamoic acid (14.0 g, 99.0%).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
In various embodiments, provided herein are pamoate salts of monoamine Anti-Parkinsons disease agents including rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and safinamide, pharmaceutical composition comprising the same, methods of preparing the same, and methods of using the same. For example, the pamoate salt herein can be characterized by a molar ratio of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, or safinamide to pamoic acid of about 1:1 or about 2:1. The pamoate salt herein can also be crystalline including anhydrous, hydrate or solvate forms, or their polymorphs, or amorphous. The pamoate salts described herein can provide a long acting and/or extended release profile of the monoamine agents tor the treatment of Parkinsons disease (PD). Thus, also provided herein are methods of preparing a long acting and/or extended release injectable formulation of the monoamine agents using their respective pamoate salts. And in some embodiments, provided herein are methods of treating a subject in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and/or safinamide.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/639,170, filed Feb. 14, 2020, now U.S. Pat. No. 11,234,961, issued Feb. 1, 2022, which is the U.S. National Phase of International Application No. PCT/US2018/046916, filed Aug. 17, 2018, which claims benefit of U.S. Provisional Application No. 62/546,984, filed on Aug. 17, 2017, the content of each of which is incorporated herein by reference in its entirety.
- In various embodiments, the present invention generally relates to pamoate salts of anti-Parkinson's disease agents, for example, pamoate salts of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and/or safinamide, pharmaceutical compositions comprising such salts, methods of preparing such salts, and methods of treating a subject in need thereof with such salts and compositions.
- Parkinson's disease (PD) is a motor system disorder of the nervous system. It is characterized as a progressive disorder that affects movement and results in the loss of dopamine-producing brain cells, causing tremor in the hands, arms, legs, jaw, and face and/or rigidity or stiffness of the limbs and trunk. The primary symptoms include muscular rigidity, slowness of movement, a resting tremor, and postural instability.
- The most common anti-Parkinson's disease drugs are to either replace the dopamine levels in the brain, mimic the actions of dopamine or slow/inhibit the degradation of dopamine in the brain. The main categories of dopaminergic drugs include dopamine agonists such as rotigotine, ropinirole, and pramipexole, of which the chemical structures are depicted below. Drugs from the category of monoamine oxidase-B (MAO-B) inhibitors such as selegiline, rasagiline, and safinamide (see chemical structures below) increase the level of dopamine in the basal ganglia by blocking its metabolism. These drugs inhibit MAO-B which breaks down dopamine secreted by the dopaminergic neurons. The reduction in MAO-B activity results in increased L-DOPA in the nervous system thus alleviating the symptom from PD.
- Currently available treatment of PD from the dopamine agonists and MAO-B inhibitors typically provide for daily oral administration. However, there is a need for a better dosing regimen of anti-PD drugs which can, for example, increase patient compliance and/or reduce side effects.
- 00061 In various embodiments, the present invention provides a variety of solid state forms, such as pamoate salts of anti-Parkinson's disease agents, e.g., monoamine anti-Parkinson's disease agents (hereinafter “monoamine agent(s)”), in different novel polymorphic forms, and more particularly, pamoate salts of rotigotine, pamoate salts of ropinirole, pamoate salts of pramipexole, pamoate salts of selegiline, pamoate salts of rasagiline, and/or pamoate salts of safinamide. In some embodiments, the present invention also provides pharmaceutical compositions comprising one or more of such salts, methods of preparing such salts, and methods of treating a subject or patient (such as a human) in need thereof with one or more of such salts and pharmaceutical compositions. In some embodiments, the present invention also provides formulations comprising one or more of the pamoate salts of the monoamine agents with a long acting and/or extended release profile. In any of the embodiments described herein, the monoamine agent can be rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and/or safinamide. In any of the embodiments described herein, the monoamine agent can also be ropinirole, pramipexole, or rotigotine.
- In some embodiments, the present invention provides novel pamoate salts, e.g., in different polymorphic forms, of monoamine agents. In some embodiments, the molar ratio of the monoamine agent's free base to pamoic acid is about 1:1 (which is referred to herein as the mono-pamoate salt of the monoamine agent). In some embodiments, the molar ratio of the monoamine agent's free base to pamoic acid is about 2:1 (which is herein referred as the semi-pamoate salt of the monoamine agent). In some embodiments, the pamoate salt of the monoamine agent is (1) crystalline, including anhydrous, hydrate, solvate forms and their polymorphs, or (2) amorphous. In some embodiments, the above salts can be especially useful in preparing a formulation, such as an extended release formulation (or composition) in which the release rate is minimally dependent on the pH of the environment at the injection site.
- In some embodiments, the present invention provides a pharmaceutical composition comprising a pamoate salt of a monoamine agent and at least one pharmaceutically acceptable carrier. In some embodiments, the carrier is a viscous aqueous or nonaqueous carrier.
- In some embodiments, the present invention provides a method of preparing a pamoate salt of a monoamine agent comprising treating or mixing the monoamine agent with pamoic acid or treating or mixing a salt of the monoamine agent with a pamoate salt in a solvent.
- In some embodiments, the present invention provides a method of treating a subject having syndrome associated with Parkinson's disease comprising administering a therapeutically effective amount of a pamoate salt of a monoamine agent or a pharmaceutical composition comprising a pamoate salt of a monoamine agent and at least one pharmaceutically acceptable carrier to a subject in need of treatment thereof. In some embodiments, the composition is administered by injection. In some particular embodiments, the composition is administered intramuscularly or subcutaneously.
- In some embodiments, the present invention provides a formulation (or composition) comprising a pamoate salt of a monoamine agent as an active ingredient or active agent, and one or more pharmaceutically acceptable carriers. In some embodiments, the formulation (or composition) can meet the unmet need for a stable, pharmaceutically suitable formulation with a controlled and/or sustained release rate which can be useful as a depot formulation or for intramuscular or subcutaneous use.
- Additional embodiments and advantages of the disclosure will be set forth, in part, in the description that follows, and will flow from the description, or can be learned by practice of the disclosure. It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only, and are not restrictive of the invention as claimed.
- Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention.
-
FIG. 1 depicts an X-ray powder diffraction (“XRPD”) spectrum of ropinirole pamoate Form A (1:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of DMSO and water. -
FIG. 2 depicts a differential scanning calorimetry (“DSC”) thermogram of ropinirole pamoate Form A (1:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture DMSO and water. -
FIG. 3 depicts an XRPD spectrum of ropinirole pamoate Form B (1:1 molar ratio of ropinirole to pamoic acid) obtained from heating materials depicted inFIGS. 1 and 2 at 170° C. for 30 minutes. -
FIG. 4 depicts a DSC thermogram of ropinirole pamoate Form B (1:1 molar ratio of ropinirole to pamoic acid) obtained from heating materials depicted inFIGS. 1 and 2 at 170° C. for 30 minutes. -
FIG. 5 depicts an XRPD spectrum of ropinirole pamoate Form C (2:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of ethanol, water and PEG6000. -
FIG. 6 depicts a DSC thermogram of ropinirole pamoate Form C (2:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of ethanol, water and PEG6000. -
FIG. 7 depicts an XRPD spectrum of ropinirole pamoate Form D (1:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of DMSO and acetonitrile. -
FIG. 8 depicts a DSC thermogram of ropinirole pamoate Form D (1:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of DMSO and acetonitrile. -
FIG. 9 depicts an XRPD spectrum of ropinirole pamoate Form E (2:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of ethanol, water and poly(allylamine hydrochloride). -
FIG. 10 depicts a DSC thermogram of ropinirole pamoate Form E (2:1 molar ratio of ropinirole to pamoic acid) obtained from a mixture of ethanol, water and poly(allylamine hydrochloride). -
FIG. 11 depicts an XRPD spectrum of rotigotine pamoate Form I (1:1 molar ratio of rotigotine to pamoic acid) obtained from a mixture of ethanol, acetone, and n-heptane. -
FIG. 12 depicts a DSC thermogram of rotigotine pamoate Form I (1:1 molar ratio of rotigotine to pamoic acid) obtained from a mixture of ethanol, acetone, and n-heptane. -
FIG. 13 depicts an XRPD spectrum of pramipexole pamoate Form 1 (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and water. -
FIG. 14 depicts a DSC thermogram of pramipexole pamoate Form 1 (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and water. -
FIG. 15 depicts an XRPD spectrum of pramipexole pamoate Form 2 (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and methanol. -
FIG. 16 depicts a DSC thermogram of pramipexole pamoate Form 2 (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and methanol. -
FIG. 17 depicts an XRPD spectrum of pramipexole pamoate Form 3 (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of ethyl acetate. -
FIG. 18 depicts a DSC thermogram of pramipexole pamoate Form 3 (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of ethyl acetate. -
FIG. 19 depicts an XRPD spectrum of pramipexole pamoate Form 4 (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of tetrahydrofuran. -
FIG. 20 depicts a DSC thermogram of pramipexole pamoate Form 4 (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of tetrahydrofuran. -
FIG. 21 depicts a 1H-NMIR spectrum of pramipexole pamoate (1:1 molar ratio of pramipexole to pamoic acid) obtained from a mixture of acetone and water. -
FIG. 22 depicts a 1H-NMIR spectrum of pramipexole pamoate (2:1 molar ratio of pramipexole to pamoic acid) obtained from a solution of tetrahydrofuran. -
FIG. 23 depicts a 1H-NMIR spectrum of Ropinirole pamoate (1:1 molar ratio of Ropinirole to pamoic acid) obtained from Example 1. -
FIG. 24 depicts a 1H-NMIR spectrum of Ropinirole pamoate (2:1 molar ratio of Ropinirole to pamoic acid) obtained from Example 3. -
FIG. 25 depicts a 1H-NMR spectrum of Rotigotine pamoate (1:1 molar ratio of Rotigotine to Pamoic acid) obtained from Example 6. -
FIG. 26 depicts a 1H-NMIR spectrum of pramipexole pamoate (2:1 molar ratio of pramipexole to pamoic acid) obtained from Example 9. - Prior to describing the details of the various embodiments of the invention, it is to be understood that the present invention is not limited in its application to the details of construction and the arrangement of components set forth in the following descriptions. The invention is capable of other embodiments and of being practiced or of being carried out in various ways by the ones skilled in the art.
- It is also specifically understood that any numerical value recited herein includes all values from the lower value to the upper value, i.e., all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in the present application.
- Currently available treatment of PD from the dopamine agonists and MAO-B inhibitors typically provide for daily oral administration. For example, pramipexole, a widely used dopamine agonist for the last decade as both monotherapy for patients with early Parkinson's disease as well as for patients with more advanced disease, is administered either three times a day or once daily. Unfortunately, development of motor and non-motor complications during the course of Parkinson's disease represents a major challenge for the current therapeutic management (M. Senek, D. Nyhohn, CNS Drugs. 28(1):19-27, 28314). At advanced disease stages, patients frequently experience PD symptoms-such as bradykinesia- and dyskinesias, in response to fluctuations in drug concentrations. Studies indicated that continuous infusion of the dopamine agonist or intestinal infusion of levodopa reduce such fluctuations in both pharmacokinetics and motor function. These studies suggested that the continuous delivery of anti-PD drugs such as dopamine agonists would provide significant benefits alleviating the motor and non-motor complications. To these objectives, the effort has been made to develop continuous delivery formulation such as transdermal delivery of rotigotine and continuous subcutaneous infusion of apomorphine to provide more continuous drug concentrations, sustained benefits and minimized side effects. However, these regimens are far less optimal only providing daily short duration of continuous drug concentrations. Furthermore, long releasing regimen of more than 24 hours would also help patients with compliance as the patients with advanced PD are often non-compliant, making it difficult to assess whether or not a patient has received the proper dosage of medication. Taken together, there is still a significant benefit and unmet medical need to develop continuous drug delivery formulation of longer than 24 hours (e.g. extended release for 7 days) to better alleviate motor and non-motor complications for the PD patients.
- Monoamine anti-PD agents are weak organic bases. In an alkaline solution (high pH), they exist as the free base form. Aqueous solubility of the monoamine agents increase with decreasing pH of the solution due to an increasing fraction of the drug being ionized. At high concentrations of the ionized drug (protonated amine), the salt form will precipitate out due to exceeding solubility product (Ksp). The nature of the drug and counter-ion determine the Ksp and the associated solid state properties of the salt.
- There are a wide range of counter-ions to prepare salts of bases using inorganic and organic acids. The most frequently used anions to form a salt of a basic drug is the hydrochloride form. For example, Requip XL, an extended-release tablet and a commercial product of dopamine agonist ropinirole for oral administration, is a hydrochloride salt. Transdermal patch of ropinirole also use its hydrochloride salt as active pharmaceutical ingredient (API) (U.S. Pat. No. 5,807,570 by Chen et al.). In the extended release tablet formulation, pramipexole dihydrochloride monohydrate was dispersed in a matrix comprising a hydrophilic polymer to achieve 24 hours release (US patent Nos. 7695734 by Friedl et al. and 8399016 by Amidon et al.). Using benzene sulfonic acid salts of pramipexole has also been described in U.S. Pat. No. 7,365,086 by Eupen et al. as alternative pharmaceutical active agents. The administration of rotigotine hydrochloride in depot form has been described in the U.S. Pat. No. 8,604,076 by Rimpler et al. The depot regimen was intended to provide therapeutically significant plasma levels of rotigotine over a period of at least 24 hours after administration to a patient. These salts of the monoamine agents were prepared to improve physical properties including stability, solubility or increased dissolution rate for administration. The selection of the respective salts rendered them desirable properties for immediate or extended release dosage form. However, these formulations, even with extended release format, are administered for no longer than 24 hours. As a result, one objective is to provide improved methods of delivering the monoamine agents significantly less frequently than the current 24-hour dosing interval and formulations can be manufactured in a cost effective manner.
- The present inventor has discovered that it is desirable to formulate the monoamine agents, e.g., in a depot formulation or as an injectable formulation such as an intramuscular or subcutaneous formulation, to assure consistent and proper dosage of the drug substance and to maximize the clinical benefits through maintaining a sustained and continuous drug concentration and improve patient compliance.
- It is known that the pH of muscle tissue can fluctuate with exercise, stress, and injury which may impact drug solubility, and thus the rate of absorption of injectable drugs. Therefore, in some embodiments, it is also desirable to develop an injectable extended release formulation in which the release rate of the active ingredient is minimally dependent on pH fluctuation, such as those related to exercise, stress, and/or injury.
- In some embodiments, the present inventor has found that a solid state or solid forms of anti-Parkinson's disease agents such as a monoamine anti-Parkinson's disease (anti-PD) agent pamoate salt, can be advantageous. Among other advantages, pamoate salts of the monoamine agents with specific polymorphic form and particle size distribution in a suitable formulation can provide a desired long acting and/or extended release profile. Such pamoate salts of the monoamine agent can provide an alternative and more desirable dosing regimen for treatment of patients suffering from Parkinson's disease (PD). It will also have superior drug absorption and distribution profiles compared to the existing oral drug products by providing a continuous delivery of drug, which would maintain stable plasma drug levels and reduce maximum to minimum plasma drug concentration ratio during dosing intervals, thus, ultimately improve safety profile and enhance clinical effectiveness.
- The chemical structure of pamoic acid is:
- The molecular weight of pamoic acid is 388 g/mol, the pKa1 is 2.51, and pKa2 is 3.1. With respect to the chemical structure of pamoic acid, both carboxylic counter ions can form salt with the amine of the monoamine agents, resulting in a molar ratio of the monoamine agents to pamoic acid of about 1:1 or about 2:1, such as those specified in
FIGS. 1-20 . - In one embodiment, the invention provides pamoate salts of anti-PD agents such as monoamine anti-PD agents and compositions and formulations containing said pamoate salts. Preferably, the pamoate salt is characterized by a molar ratio of the monoamine agent to pamoic acid of about 1:1 or about 2:1. The pamoate salt can be crystalline, anhydrous, hydrated, solvated, or amorphous.
- In another embodiment, the invention provides pamoate salt of ropinirole, e.g., five crystalline Forms, Form A to Form E, of pamoate salt of ropinirole. Forms A, B, and D of pamoate salt of ropinirole each has a molar ratio of ropinirole to pamoic acid of about 1:1, whereas Forms C and E of pamoate salt of ropinirole each has a molar ratio of ropinirole to pamoic acid of about 2:1. Pamoate salts of ropinirole can be prepared by those skilled in the art in view of the present disclosure, see e.g., the Examples section. For example, Forms A, B, C, D, E of pamoate salt of ropinirole can be prepared by following the procedures described in Examples 1-5 in the Examples section, respectively.
- In some embodiments, the crystalline Form A to Form E of pamoate salt of ropinirole can be characterized by one or more of the following properties: (1) an X-ray powder diffraction pattern having peak(s) expressed as 2-theta from 3 to 40 degrees substantially in accordance with (e.g., within ±0.2° 2-theta) one or more (e.g., two or more, three or more, etc., e.g., 1, 2, 3, 4, 5, 6, or more) of the main peaks shown in
FIGS. 1, 3, 5, 7, 9 , respectively, for each crystalline form; (2) an X-ray powder diffraction pattern substantially in accordance with those shown inFIGS. 1, 3, 5, 7, 9 , respectively, for each crystalline form; (3) a differential scanning calorimetry thermogram pattern substantially in accordance with those shown inFIGS. 2, 4, 6, 8, 10 , respectively, for each crystalline form; and (4) any combinations of (1), (2) and (3), respectively for each crystalline form. As used herein, “main peaks” refer to peaks in an MOD spectrum (e.g., as shown in the FIGs and Tables herein) that have a relative intensity (height) of about 15% or more, preferably, about 30% or more (e.g., 35% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more). In some embodiments, “main peaks” refers to peaks in an XRPD spectrum (e.g., as shown in the FIGs and Tables herein) that have a relative intensity (height) of about 80% or more. - For example, in some embodiments, ropinirole pamoate in crystalline Form A can be characterized by an XRPD spectrum having one or more (e.g., 4 or more, 6 or more, 8 or more, 10 or more, 12 or more, or all of) of the following peaks: 4.3, 9.8, 11.5, 14.4, 16.0, 17.1, 18.6, 19.1, 20.5, 21.0, 23.1, 23.8, 26.5, and 26.9, ±0.2° 2-theta. In some embodiments, ropinirole pamoate in crystalline Form A can be characterized by an XRPD spectrum having one or more (e.g., 2 or more, 4 or more, 6 or more, or all of) of the following peaks: 4.3, 9.8, 17.1, 18.6, 19.1, 20.5, 21.0, and 23.1, ±0.2° 2-theta. In some embodiments, ropinirole pamoate in crystalline Form A can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 4.3, 17.1, 18.6, and 20.5, ±0.2° 2-theta.
- In some embodiments, ropinirole pamoate in crystalline Form B can be characterized by an XRPD spectrum having one or more (e.g., 4 or more, 6 or more, 8 or more, 10 or more, or all of) of the following peaks: 9.4, 11.5, 12.0, 12.7, 15.6, 16.4, 17.2, 18.7, 21.0, 23.1, 23.4, and 26.2, ±0.2° 2-theta. In some embodiments, ropinirole pamoate in crystalline Form B can be characterized by an XRPD spectrum having one or more (e.g., 2 or more, 4 or more, 6 or more, or all of) of the following peaks: 11.5, 12.0, 12.7, 16.4, 21.0, 23.1, 23.4, and 26.2, ±0.2° 2-theta. In some embodiments, ropinirole pamoate in crystalline Form B can be characterized by an XRPD spectrum having one or more (e.g., 2 or more, 4 or more, or all of) of the following peaks: 11.5, 16.4, 21.0, 23.1, 23.4, and 26.2, ±0.2° 2-theta.
- In some embodiments, ropinirole pamoate in crystalline Form C can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 8.0, 9.5, 16.1, and 18.8, ±0.2° 2-theta. In some embodiments, ropinirole pamoate in crystalline Form C can be characterized by an XRPD spectrum having peaks at 16.1 and 18.8, ±0.2° 2-theta.
- In some embodiments, ropinirole pamoate in crystalline Form D can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, or 6) of the following peaks: 14.3, 17.9, 21.5, 22.4, 24.8, and 25.2, ±0.2° 2-theta. In some embodiments, ropinirole pamoate in crystalline Form D can be characterized by an XRPD spectrum having one or more (1, 2, or 3) of the following peaks: 14.3, 17.9, and 25.2, ±0.2° 2-theta, for example, ropinirole pamoate in crystalline Form D can be characterized by an XRPD spectrum having a peak at 17.9±0.2° 2-theta.
- In some embodiments, ropinirole pamoate in crystalline Form E can be characterized by an XRPD spectrum having one or more (e.g., 4 or more, 6 or more, 8 or more, 10 or more, or all of) of the following peaks: 11.1, 11.7, 12.0, 15.5, 18.8, 19.6, 20.2, 21.0, 22.9, 23.6, 26.1, and 26.6, ±0.2° 2-theta. In some embodiments, ropinirole pamoate in crystalline Form E can be characterized by an XRPD spectrum having one or more (e.g., 2 or more, 4 or more, or all of) of the following peaks: 11.1, 11.7, 12.0, 21.0, 26.1, and 26.6, ±0.2° 2-theta. In some embodiments, ropinirole pamoate in crystalline Form E can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, or 3) of the following peaks: 11.7, 12.0, and 21.0, ±0.2° 2-theta.
- In some embodiments, each of the crystalline Form A to Form E of pamoate salts of ropinirole can be substantially pure, for example, each form can be substantially free of other crystalline or amorphous forms of pamoate salts of ropinirole (e.g., less than 20%, less than 10%, less than 5%, or not detectable with the XRPD method described herein). However, in some embodiments, each of the crystalline Form A to Form E of pamoate salts of ropinirole can exist in a mixture with one or more other forms of pamoate salts of ropinirole, crystalline or amorphous.
- In yet another embodiment, the invention relates to pamoate salt of rotigotine, e.g., crystalline Form I of pamoate salt of rotigotine, which has a molar ratio of rotigotine to pamoic acid of about 1:1. Pamoate salts of rotigotine can be prepared by those skilled in the art in view of the present disclosure, see e.g., the Examples section. For example, Form I of pamoate salt of rotigotine can be prepared by following the procedures described in Example 6 in the Examples section.
- In some embodiments, the crystalline Form I of pamoate salt of rotigotine can be characterized by one or more of the following properties: (1) an X-ray powder diffraction pattern having peak(s) expressed as 2-theta from 3 to 40 degrees substantially in accordance (e.g., within ±0.2° 2-theta) one or more (e.g., two or more, three or more, etc., e.g., 1, 2, 3, 4, 5, 6, or more) of with the main peaks shown in
FIG. 11 ; (2) an X-ray powder diffraction pattern substantially in accordance with that shown inFIG. 11 ; (3) a differential scanning calorimetry thermogram pattern substantially in accordance with that shown inFIGS. 12 ; and (4) any combinations of (1), (2) and (3). For example, in some embodiments, Form I of pamoate salt of rotigotine can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) of the following peaks: 4.6, 9.3, 17.5, 18.7, 24.2, 26.4, 28.2, and 29.6, ±0.2° 2-theta. In some embodiments, Form I of pamoate salt of rotigotine can be characterized by an XRPD spectrum having one or both peaks at 4.6 and 9.3, ±0.2° 2-theta. In some embodiments, the crystalline Form I of pamoate salt of rotigotine can be substantially pure, for example, substantially free of other crystalline or amorphous forms of pamoate salt of rotigotine (e.g., less than 20%, less than 10%, less than 5%, or not detectable with the XRPD method described herein). However, in some embodiments, the crystalline Form I of pamoate salt of rotigotine can exist in a mixture with one or more other forms of pamoate salt of rotigotine, crystalline or amorphous. - In yet another embodiment, the invention relates to pamoate salt of pramipexole, e.g., crystalline forms,
Form 1 to Form 4, of pamoate salt of pramipexole. Pamoate salts of pramipexole can be prepared by those skilled in the art in view of the present disclosure, see e.g., the Examples section. For example, Forms 1-4 of pamoate salt of pramipexole can be prepared by following the procedures described in Examples 7-10 in the Examples section, respectively. -
Forms crystalline Form 1 to Form 4 of pamoate salt of pramipexole can be characterized by one or more of the following properties: (1) an X-ray powder diffraction pattern having peak(s) expressed as 2-theta from 3 to 40 degrees substantially in accordance with (e.g., within ±0.2° 2-theta) one or more (e.g., two or more, three or more, etc., e.g., 1, 2, 3, 4, 5, 6, or more) of the main peaks shown inFIG. 13, 15, 17, 19 , respectively, for each crystalline form; (2) an X-ray powder diffraction pattern substantially in accordance with those shown inFIG. 13, 15, 17, 19 , respectively, for each crystalline form; (3) a differential scanning calorimetry thermogram pattern substantially in accordance with those shown inFIG. 14, 16, 18, 20 , respectively for each crystalline form; and (4) any combinations of (1), (2) and (3). - In some embodiments,
Form 1 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9) of the following peaks: 7.7, 11.8, 13.8, 15.3, 18.9, 21.1, 23.1, 23.7, and 26.4, ±0.2° 2-theta. In some embodiments,Form 1 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, or 3) of the following peaks: 13.8, 15.3, and 21.1, ±0.2° 2-theta. - In some embodiments,
Form 2 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) of the following peaks: 12.0, 15.0, 17.2, 20.4, 20.9, 22.5, 23.3, and 25.4, ±0.2° 2-theta. In some embodiments,Form 2 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, or 6) of the following peaks: 12.0, 15.0, 20.4, 20.9, 22.5, and 23.3, ±0.2° 2-theta. In some embodiments,Form 2 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 12.0, 15.0, 20.4, and 20.9, ±0.2° 2-theta. - In some embodiments, Form 3 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) of the following peaks: 10.7, 12.7, 13.5, 14.9, 16.3, 18.1, 18.7, and 22.3, ±0.2° 2-theta. In some embodiments, Form 3 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, or 6) of the following peaks: 10.7, 12.7, 13.5, 14.9, 18.7, and 22.3, ±0.2° 2-theta. In some embodiments, Form 3 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 10.7, 12.7, 13.5, and 14.9, ±0.2° 2-theta.
- In some embodiments, Form 4 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of the following peaks: 6.1, 13.5, 14.9, 17.9, 18.9, 21.3, 21.8, 22.4, 23.2, and 24.0, ±0.2° 2-theta. In some embodiments, Form 4 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, 4, 5, or 6) of the following peaks: 6.1, 17.9, 18.9, 21.3, 23.2, and 24.0, ±0.2° 2-theta. In some embodiments, Form 4 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having one or more (e.g., 1, 2, 3, or 4) of the following peaks: 6.1, 17.9, 21.3, and 23.2, ±0.2° 2-theta. In some embodiments, Form 4 of pamoate salt of pramipexole can be characterized by an XRPD spectrum having the following peaks: 6.1 and 17.9, ±0.2° 2-theta.
- In some embodiments, each of the
crystalline Form 1 to Form 4 of pamoate salt of pramipexole can be substantially pure, for example, each form can be substantially free of other crystalline or amorphous forms of pamoate salt of pramipexole (e.g., less than 20%, less than 10%, less than 5%, or not detectable with the XRPD method described herein). However, in some embodiments, each of thecrystalline Form 1 to Form 4 of pamoate salt of pramipexole can exist in a mixture with one or more other forms of pamoate salt of pramipexole, crystalline or amorphous. - In some embodiments, the invention further provides a pharmaceutical composition comprising one or more of the pamoate salts of the monoamine anti-PD agents (e.g., any of those described herein, e.g., Forms A-E of pamoate salt of ropinirole, Form I of pamoate salt of rotigotine, Forms 1-4 of pamoate salt of pramipexole) and at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is an intramuscularly or subcutaneously injectable formulation. In one preferred embodiment, the pharmaceutical composition is an extended release formulation comprising pamoate salts of the monoamine agents and a polymer (e.g., a release control polymer). Polymers suitable for use in the extended release formulations include any of those known in the art. Some of which can be found, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co. In some embodiments, the extended release can be based on the slow dissolution rate of the pamoate salts herein. In some embodiments, the extended release formulation can also be free or substantially free of a polymer, for example, the extended release formulation can be free or substantially free a release control polymer.
- In another embodiment, the pharmaceutically acceptable carrier is a viscous aqueous or nonaqueous fluid. In some embodiments, the viscous aqueous or nonaqueous fluid can have a viscosity of at least 20 cp at 20° C. In some embodiments the viscous aqueous or nonaqueous fluid can have a viscosity at 20° C. of at least about 30 cp, e.g., about 40 cp, about 50 cp, about 60 cp, at least about 40 cp, at least about 50 cp, or at least about 60 cp. In a preferred embodiment, the pharmaceutical composition releases an effective amount of the active agent (one or more of the pamoate salts of the monoamine agents as described herein) over a period of at least about 24 hours or at least about 48 hours. In another preferred embodiment, the active agent in the pharmaceutical composition has a duration of efficacy of at least about 7 days or at least about 14 days.
- The invention further relates to methods of treating a subject having syndrome associated with Parkinson's disease, such as a warm blood mammal (such as a human patient or subject characterized as having Parkinson's disease). The method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a pamoate salt of the monoamine agent (e.g., any of those described herein) and at least one pharmaceutically acceptable carrier.
- In various embodiments, the present inventor discovered that the pharmaceutically acceptable salts of the monoamine agents formed using pamoic acid as a counterion surprisingly exhibit very low solubility (KT). This low solubility can be highly desirable when used in a pharmaceutical composition to provide for extended release of the pamoate salt of the monoamine agents, for example, when administered intramuscularly or subcutaneously. In some embodiments, the pharmaceutical compositions of the present invention include various pharmaceutical dosage forms for the purposes of administering dosage to a subject (such as a warm blooded mammal, such as a human) in need of treatment of Parkinson's disease. In some embodiments, to prepare the pharmaceutical compositions of the present invention, a pharmaceutically effective amount of one or more pamoate salts of the monoamine agent (as the active ingredient or active agent) are combined with one or more pharmaceutically acceptable excipients. The pharmaceutically acceptable excipients used are generally less critical, are well known in the art, and may take a wide variety of forms depending on the form of preparation desired for administration. In some embodiments, these pharmaceutical compositions are provided in a unit dosage form suitable for administration.
- Administration of the compositions of the present invention can be, for example, parenterally, such as by subcutaneous or intramuscular injection or implantation. For administration, the pamoate salts of the monoamine agents can be, for example, suspended in an aqueous solvent, which can further comprise a wetting agent, such as the polyoxyethylene derivatives of sorbitan esters, e.g. polysorbate 80 (Tween® 80) and polysorbate 20 (Tween® 20), lecithin, polyoxyethylene- and polyoxypropylene ethers, sodium deoxycholate, and the like; a suspending agent such as a cellulose derivate, e.g. methylcellulose, sodium carboxymethylcellulose and hydroxypropyl methylcellulose, polyvinylpyrrolidone, alginates, chitosan, dextran, gelatin, polyethylene glycols, polyoxyethylene- and polyoxypropylene ethers and the like; an acid, e.g. hydrochloric acid, and the like; a base, e.g. sodium hydroxide, and the like; a buffer comprising a mixture of appropriate amounts of an acid such as phosphoric, succinic, tartaric, lactic, acetic, maleic or citric acid, and a base, in particular sodium hydroxide or disodium hydrogen phosphate; a preservative, e.g. benzoic acid, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorbutol, a gallate, a hydroxybenzoate, EDTA, phenol, chlorocresol, metacresol, benzothonium chloride, myristyl-.gamma.-piccolinium chloride, phenylmercuri acetate, thimerosal and the like; a tonicity adjusting agent, e.g. sodium chloride, dextrose, mannitol, sorbitol, lactose, sodium sulfate, and the like. In some embodiments, the pamoate salts of the monoamine agents can also be formulated in one or more oils. Appropriate oils that can be used include fixed oils, for example, peanut oil, sesame oil, cottonseed oil, corn oil, safflower oil, castor oil, ethyloleate, soybean oil, synthetic glycerol esters of long chain fatty or medium chain acids and mixtures of these and other oils. In some embodiments, thickening agents can be added to the composition, e.g. aluminum monostearate, ethylcellulose, triglycerides, hydrogenated castor oil, and the like.
- In view of the usefulness of the pamoate salts of the monoamine agents in the treatment of Parkinson's diseases, in some embodiments, the present invention further provides a method of treating warm-blooded mammals (such as humans), suffering from PD. In some embodiments, the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising at least one pamoate salt of the monoamine agents as described herein and one or more pharmaceutically acceptable excipients.
- In some embodiments, the pharmaceutical compositions described herein can be administered to a subject in need of treatment of Parkinson's disease as a long acting composition. In one embodiment, the active agent is released from the composition over a period of at least about 24 hours, preferably at least about 48 hours. The active agent can also be administered in an extended release composition. In one embodiment, the extended release composition releases the active agent over a period of at least about 7 days, preferably at least about 14 days, alternatively for at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 6 weeks or at least 8 weeks. The composition can be administered by injection, such as intramuscularly or subcutaneously. In one embodiment, the compositions can be administered as a single or sole dose. However, in some embodiments, the compositions described herein are particularly beneficial for those subjects in need of treatment of Parkinson's disease that require constant or chronic therapy, such as those subjects that receive repeated doses over several weeks or months or more. In such dosing regimens, the method can comprise: (1) administering as first dose an first extended release composition containing one or more of the pamoate salts of the monoamine agents as described herein followed by (2) administering as a second dose (and as subsequence doses if necessary), a second extended release composition. The second extended release composition can be the same, substantially the same or different than the first extended release composition. Specifically, in some embodiments, the second extended release composition can include as the active agent of one or more of the pamoate salts of the monoamine agents as described herein or an active agent that is other than the pamoate salts of the monoamine agents as described herein. The second composition can be administered at about 7 days, or more, such as at least about 14 days, or at least about 21 days, after the first administration of the first extended release composition, where the first administration results in the release of active agent for a period of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or more.
- As used herein, the term “about” modifying an amount related to the invention refers to variation in the numerical quantity that can occur, for example, through routine testing and handling; through inadvertent error in such testing and handling; through differences in the manufacture, source, or purity of ingredients employed in the invention; and the like. As used herein, “about” a specific value also includes the specific value, for example, about 10% includes 10%. Whether or not modified by the term “about”, the claims include equivalents of the recited quantities. In one embodiment, the term “about” means within 20% of the reported numerical value.
- As used herein, the term “individual”, “subject” or “patient” refers to a warm blooded animal which is afflicted with a particular disease state. Warm blooded animals include mammals, such as humans.
- The term “effective amount” or “therapeutically effective amount” is defined as an amount resulting in the improvement of any parameters or clinical symptoms. In any of the embodiments described in, the term “effective amount” or “therapeutically effective amount” can be an amount resulting in the improvement of any parameters or clinical symptoms associated with Parkinson's disease. The actual dose may vary with each patient and does not necessarily indicate a total elimination of all disease symptoms. A therapeutically effective amount of the compound used in the methods described herein can be readily determined by one skilled in the art, such as an attending physician, by observing results obtained under analogous circumstances and by using conventional techniques. In determining the therapeutically effective dose, the attending physician considers a number of factors, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
- Similarly, the term “duration of efficacy” or “therapeutically effective plasma concentration” of a monoamine for a given time period should be understood as such that during such time period, the respective monoamine is present (e.g., in the plasma of a subject treated with the pamoate salt herein) in an amount and/or concentration sufficient to result in the improvement of any parameters or clinical symptoms, for example, the improvement of any parameters or clinical symptoms associated with Parkinson's disease.
- Preferred amounts and modes of administration can be readily be determined by one skilled in the art depending upon the particular characteristics of the compound selected, the disease state to be treated, the stage of the disease, and other relevant circumstances using formulation technology known in the art, described for example in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co.
- Pharmaceutical compositions can be manufactured utilizing routine techniques known in the art. Typically a therapeutically effective amount of the compound (salt) will be combined with a pharmaceutically acceptable carrier.
- The pharmaceutical compositions of the present invention can be administered parenterally. For instance, they can be administered by injection. Preferred methods of parenteral administration include intramuscular and subcutaneous injection.
- For parenteral administration, the compounds (salt) can be dissolved in a physiologically acceptable pharmaceutical carrier and administered as either a solution or a suspension. Viscous injectable carriers are preferred, having for example, a viscosity of at least 20 cp at 20° C. In other embodiments, the fluid phase of the suspension has a viscosity at 20° C. of at least about 30 cp, e.g., about 40 cp, about 50 cp, about 60 cp, at least about 40 cp, at least about 50 cp, or at least about 60 cp. The composition can also comprise a viscosity enhancing agent, a density enhancing agent, a tonicity enhancing agent, and/or a wetting agent. Suitable pharmaceutical carriers include water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative, or synthetic origin. The pharmaceutical carrier may also contain preservatives, and buffers as known in the art.
- When the composition is to be used as an injectable material, including, but not limited to, needle-less injection, it can be formulated into a conventional injectable carrier. Suitable carriers include biocompatible and pharmaceutically acceptable solutions, emulsions or suspensions.
- In another embodiment, the formulation can be surgically implanted. Such formulations can include any of the well-known biodegradable and bioerodible carriers, such as polylactides, poly-lactide-co-glycolides and collagen formulations. Such materials can be in the form of solid implants, sponges, and the like. In any event, for local use of the materials, the active ingredients usually are present in the carrier or excipient in a weight ratio of from about 1:1000 to 1:20,000, but are not limited to ratios within this range.
- In some embodiments, the present invention also provides methods of making pamoate salts of the monoamine agents. Specifically, pamoate salts of the monoamine agents can be prepared in a variety of different ways. For example, in one embodiment, pamoate salts of the monoamine agents can be prepared directly by treating or mixing the monoamine agents (such as a free base) with pamoic acid in a solvent (such as water, ethanol or DMSO). In another embodiment, pamoate salts of the monoamine agents can be prepared by treating or mixing the monoamine agents salt (such as a hydrochloride salt) with a pamoate salt (such as disodium pamoate) in one or more solvents. For example, the pamoate of the monoamine agents can be prepared by adding a solution of disodium pamoate, or other pamoate salt in an appropriate solvent, such as water, to a solution of the monoamine agent hydrochloride and leaving the solution to stir for a period of time, such as, for example, about 3 or 12 hours, until precipitation occurs. Alternatively, other methods such as evaporation, slurry, anti-solvent, cooling and hydration can also be used to crystalize the salt. Solvents useful for preparing the pamoate salts herein include, without limitation, water, alkanols (e.g. methanol and ethanol), alkyl ketones (e.g. acetone), alkanes (e.g. n-heptane), acetonitrile, toluene, DMSO, alkyl ester (e.g. ethyl acetate), halogenated alkanes (e.g. chloroform), ethers, tetrahydrofuran (THF), 1,4-dioxane, and combinations thereof.
- In some embodiments, the present invention provides a solid state form of pharmaceutical acceptable salt of dopamine agonists rotigotine, ropinirole, and pramipexole, wherein the salt is a pamoate salt. The pamoate salt can be crystalline, anhydrous, hydrated, solvated, or amorphous. In another embodiment, the invention relates to crystalline pamoate salts of rotigotine, ropinirole, or pramipexole having or characterized by one or more of the following properties: (1) an X-ray powder diffraction pattern substantially in accordance with those shown in
FIGS. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 , respectively, for each crystalline form; (2) a differential scanning calorimetry thermogram pattern substantially in accordance with those shown inFIGS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 , respectively, for each crystalline form; and (3) a combination of (1) and (2). In some embodiments, the present invention also relates to compositions containing one or more of the above described pamoate salts of rotigotine, ropinirole, and pramipexole and pharmaceutical compositions containing said compositions and at least one pharmaceutically acceptable carrier. - In some embodiments, the present invention provides a solid state form of a pharmaceutical acceptable salt of anti-PD MAO-B inhibitors selegiline, rasagiline, and safinamide, wherein the salt is a pamoate salt. The pamoate salt can be crystalline, anhydrous, hydrated, solvated, or amorphous. In some embodiments, the present invention also provides compositions containing one or more of the above described pamoate salts of selegiline, rasagiline, and safinamide and pharmaceutical compositions containing said compositions and at least one pharmaceutically acceptable carrier.
- The following examples are intended to illustrate and not to limit the scope of the present invention.
- Preparation of Ropinirole Pamoate at a 1:1 Molar Ratio of Ropinirole to Pamoic Acid from a Mixture of DMSO and Water.
- Ropinirole (2 g, 7.7 mmol) and Pamoic Acid (2.975 g, 7.7 mmol) was added into DMSO (15 mL) with stirring to form a solution. The resultant solution was slowly added to water (500 mL) at room temperature which produced a white solid. The solid was collected on a filter, washed with water, and dried in vacuum at 40° C. to generate Ropinirole Pamoate as white solids (4.0 g, 80.4%).
- X-ray powder diffraction (“XRPD”) patterns of above solids were obtained using a Bruker D8 Advance x-ray powder diffractometer with copper Kα radiation at a wavelength of 1.54 nm. Instrumental conditions included a step size of 0.02 degree per step, a scan rate of 0.2 seconds per step, a 2-theta range of 3 to 40 degrees, a voltage of 40 kV, a current of 40 mA, and a Lynxeye detector. Samples were packed into recessed sample holders for analysis. Typically, the error margin for 2-theta values is ±0.2°. XRPD patterns for other examples herein were obtained similarly. A typical example of X-ray powder diffraction pattern and data, respectively, for the salt from Example 1 is shown in
FIG. 1 and Table 1 wherein d(A) represents the interplanar spacing. Height and Height % represent the typical relative intensities. - The differential scanning calorimetry thermogram of above solids was obtained using a TA Instrument Q200 Differential Scanning calorimeter. The measurement was controlled by “Thermal Advantage” system and data was analyzed using “Universal Analysis” software. Typical sample load ranges from 0.5 to 5 mg. The measurement is under an atmosphere of nitrogen with flow rate of 40 mL/min. System equilibrium is set at 20° C. and the temperature is then increased to 250° C. at a rate of 10° C./min. Typically, the error margin for DSC peak values is ±3° C. DSC thermograms for other examples herein were obtained similarly. A typical example of a differential scanning calorimetry thermogram for the salt from Example 1 is shown in
FIG. 2 . 1H NMR (seeFIG. 23 ) indicates that the molar ratio of Ropinirole to Pamoic Acid in the salt from Example 1 is about 1:1. -
TABLE 1 2-Theta d(A) Height Height % 4.279 20.6311 489 100.0 8.508 10.3844 131 26.8 9.750 9.0644 370 75.7 10.479 8.4352 236 48.3 11.523 7.6727 288 58.9 12.096 7.3111 134 27.4 12.748 6.9386 140 28.6 13.845 6.3908 145 29.7 14.363 6.1616 316 64.6 15.971 5.5446 319 65.2 16.504 5.3669 173 35.4 17.126 5.1732 461 94.3 17.608 5.0326 121 24.7 18.648 4.7543 400 81.8 19.146 4.6317 382 78.1 19.615 4.5222 78 16.0 20.467 4.3357 396 81.0 21.007 4.2255 369 75.5 21.553 4.1196 103 21.1 22.471 3.9533 62 12.7 23.111 3.8452 369 75.5 23.831 3.7307 274 56.0 24.328 3.6556 142 29.0 25.517 3.4879 173 35.4 26.052 3.4174 90 18.4 26.450 3.3670 342 69.9 26.910 3.3105 259 53.0 29.473 3.0281 207 42.3 29.914 2.9844 75 15.3 30.686 2.9112 55 11.2 31.494 2.8382 45 9.2 34.235 2.6170 42 8.6 38.553 2.3333 44 9.0 - Preparation of Ropinirole Pamoate at a 1:1 Molar Ratio of Ropinirole to Pamoic Acid from Heating Batches Depicted in
FIGS. 1 and 2 at 170° C. for 30 Minutes - 75 mg of ropinirole pamoate from Example 1 was placed at 170° C. for 30 minutes to give a solid of which a typical example of an X-ray diffraction pattern is shown in
FIG. 3 and Table 2. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 4 . 1H NMR indicates that the molar ratio of Ropinirole to Pamoic Acid in this solid is about 1:1. -
TABLE 2 2-Theta d(A) Height Height % 9.402 9.3986 185 54.9 11.082 7.9772 144 42.7 11.460 7.7152 307 91.1 12.004 7.3667 262 77.7 12.683 6.9738 235 69.7 13.290 6.6567 85 25.2 14.287 6.1942 138 40.9 15.549 5.6942 190 56.4 16.406 5.3988 298 88.4 17.209 5.1485 185 54.9 18.652 4.7532 187 55.5 19.367 4.5794 136 40.4 19.846 4.4698 112 33.2 20.145 4.4044 155 46.0 21.009 4.2251 315 93.5 21.367 4.1550 121 35.9 22.368 3.9713 151 44.8 23.051 3.8552 297 88.1 23.410 3.7969 337 100.0 24.172 3.6788 85 25.2 24.525 3.6267 62 18.4 25.570 3.4808 70 20.8 25.951 3.4306 110 32.6 26.228 3.3949 269 79.8 26.872 3.3150 150 44.5 27.768 3.2101 96 28.5 29.836 2.9922 117 34.7 30.898 2.8917 40 11.9 36.518 2.4585 38 11.3 38.074 2.3616 39 11.6 - Preparation of Ropinirole Pamoate at a 2:1 Molar Ratio of Ropinirole to Pamoic Acid from a Mixture of Ethanol, Water and PEG6000.
- 100 mg of ropinirole pamoate from Example 1 was dissolved at room temperature in a mixture of 14 mL of ethanol and 7 mL of water. To the solution was added 10% PEG6000 and the resultant mixture was dissolved by sonication which was then concentrated at 40° C., which produced a solid. This solid was then collected, washed, and dried. A typical example of an X-ray diffraction pattern for this solid is shown in
FIG. 5 and Table 3. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 6 . 1H NMR (seeFIG. 24 ) indicates that the molar ratio of Ropinirole to Pamoic Acid in the salt from Example 3 is about 2:1. -
TABLE 3 2-Theta d(A) Height Height % 8.026 11.0074 362 24.9 9.501 9.3008 205 14.1 10 707 8.2559 71 4.9 11.275 7.8414 92 6.3 11.837 7.4700 96 6.6 12.103 7.3067 127 8.7 13.387 6.6084 166 11.4 15.666 5.6521 170 11.7 16.073 5.5097 1227 84.5 16.844 5.2591 50 3 4 17.166 5.1613 87 6.0 17.672 5.0147 48 3.3 18.219 4.8653 89 6.1 18.773 4.7229 1452 100.0 20.394 4.3511 94 6.5 21.158 4.1957 147 10.1 21.479 4.1336 177 12.2 22.359 3.9729 47 3.2 23.052 3.8550 53 3.7 24.391 3.6463 78 5.4 25.100 3.5449 148 10.2 25.914 3.4354 54 3.7 26.277 3.3888 116 8.0 26.913 3.3101 60 4.1 27.613 3.2278 60 4.1 29.967 2.9794 68 4.7 32.473 2.7549 91 6.3 35.328 2.5385 45 3.1 - Preparation of Ropinirole Pamoate at a 1:1 Molar Ratio of Ropinirole to Pamoic Acid from a Mixture of DMSO and Acetonitrile.
- 100 mg of ropinirole pamoate from Example 1 was dissolved in 0.45 mL of dimethyl sulfoxide (DMSO). To the solution at room temperature was added 5 mL of acetonitrile. The resultant solution was then stirred at 4° C. to yield a solid, which was collected, washed, and dried. A typical example of an X-ray diffraction pattern for this solid is shown in
FIG. 7 and Table 4. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 8 . 1H NMR indicates that the molar ratio of Ropinirole to Pamoic Acid in this solid is about 1:1. -
TABLE 4 2-Theta d(A) Height Height % 9.426 9.3748 51 9.5 14.304 6.1868 129 24.0 16.106 5.4985 45 8.4 17.889 4.9544 538 100.0 18.848 4.7044 77 14.3 19.386 4.5750 59 11.0 21.453 4.1386 96 17.8 21.930 4.0496 65 12.1 22.370 3.9710 89 16.5 24.815 3.5850 102 19.0 25.248 3.5244 179 33.3 25.562 3.4819 56 10.4 28.168 3.1654 44 8.2 32.076 2.7881 39 7.2 32.436 2.7579 74 13.8 - Preparation of Ropinirole Pamoate at a 2:1 Molar Ratio of Ropinirole to Pamoic Acid from a Mixture of Ethanol, Water and Poly(Allylamine Hydrochloride).
- 100 mg of ropinirole pamoate from Example 1 was dissolved in a mixture of 14 mL of ethanol and 7 mL of water. To the solution was added 10% poly(allylamine hydrochloride). After kept evaporation at 40° C., a solid was formed and characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in
FIG. 9 and Table 5. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 10 . 1H NMR indicates that the molar ratio of Ropinirole to Pamoic Acid in this solid is about 2:1. -
TABLE 5 2-Theta d(A) Height Height % 7.281 12.1314 166 31.9 9.342 9.4591 159 30.5 10.346 8.5428 88 16.9 11.122 7 9490 365 70.1 11.685 7.5671 434 83.3 11.965 7.3905 521 100.0 12.783 6.9195 165 31.7 13.348 6.6279 99 19.0 14.800 5.9807 219 42.0 15.506 5.7099 289 55.5 15.948 5 5527 202 38.8 16.711 5.3007 122 23.4 16.992 5.2138 204 39.2 18.080 4.9024 109 20.9 18.807 4.7144 286 54.9 19.217 4.6149 95 18.2 19.612 4.5227 284 54.5 20.210 4.3902 260 49.9 21.009 4.2250 398 76.4 22.191 4.0027 165 31.7 22.571 3.9361 169 32.4 22.911 3.8785 267 51.2 23.629 3.7622 280 53.7 24.214 3 6726 185 35.5 24.691 3.6027 95 18.2 24.968 3.5633 199 38.2 25.791 3.4515 182 34.9 26.130 3.4075 320 61.4 26.636 3.3439 353 67.8 27.033 3.2957 77 14.8 27.458 3.2456 137 26.3 28.251 3.1563 46 8.8 29.223 3.0535 45 8.6 29.753 3.0003 150 28.8 32.523 2.7508 61 11.7 33.756 2.6530 61 11.7 34.561 2.5931 41 7.9 35.045 2.5584 50 9.6 37.818 2.3769 188 36.1 38.437 2.3400 38 7.3 - Preparation of Rotigotine Pamoate at a 1:1 Molar Ratio of Rotigotine to Pamoic Acid from a Mixture of Ethanol, Acetone, and n-Heptane.
- 35.2 mg of rotigotine hydrochloride salt was dissolved in a mixture of 4 mL of acetone and 1 mL of ethanol via sonication. Separately, 41 mg of sodium pamoate was dissolved in a mixture of 2 mL of ethanol and 0.4 mL of acetone. To the rotigotine hydrochloride solution was added in a dropwise manner the sodium pamoate solution. After addition and stirred for 30 minutes, 4 mL of n-heptane was added and the resultant solution was stirred overnight to generate rotigotine pamoate as crystalline solid. The solid was collected, washed with water, dried under vacuum, and characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in
FIG. 11 and Table 6. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 12 . 1H NMR (seeFIG. 25 ) indicates that the molar ratio of Rotigotine to Pamoic acid in this solid is about 1:1. -
TABLE 6 2-Theta d(A) Height Height % 4.600 19.1958 1736 100.0 8.674 10.1855 124 7.1 9.284 9.5181 935 53.9 10.499 8.4193 68 3.9 11.105 7.9608 85 4.9 13.985 6.3274 105 6.0 14.678 6.0301 78 4.5 16.619 5.3298 71 4.1 17.000 5.2113 55 3.2 17.468 5.0728 321 18.5 17.883 4.9559 58 3.3 18.681 4.7459 251 14.5 19.040 4.6572 166 9.6 20.480 4.3330 121 7.0 20.722 4.2829 118 6.8 21.641 4.1031 94 5.4 22.506 3.9473 199 11.5 23.220 3.8275 103 5.9 23.543 3.7757 96 5.5 24.248 3.6675 270 15.6 25.230 3.5269 95 5.5 25.556 3.4827 117 6.7 25.961 3.4293 189 10.9 26.403 3.3729 317 18.3 27.754 3.2116 71 4.1 28.186 3.1634 270 15.6 29.587 3.0167 257 14.8 30.919 2.8897 87 5.0 31.545 2.8338 73 4.2 33.903 2.6419 74 4.3 34.978 2.5631 56 3.2 37.465 2.3985 40 2.3 - Preparation of Pramipexole Pamoate at a 1:1 Molar Ratio of Pramipexole to Pamoic Acid from a Mixture of Acetone and Water.
- Pramipexole (3.0 g, 14.1 mmol) and Pamoic acid (2.7 g, 7.0 mmol) was dissolved by stirring at room temperature in DMSO (30 mL). The solution was then slowly added to ethyl acetate (2 L) at room temperature to generate a white solid. The solid was collected on a filter and dried in vacuum at 45° C. to give an amorphous pramipexole pamoate at a 2:1 Molar ratio of Pramipexole to Pamoic acid (4.5 g, 78.6%).
- 100 mg of above amorphous pramipexole pamoate salt was dissolved in a mixture of 3 mL of acetone and 0.5 mL of water at 60° C. The solution was slowly cooled to room temperature and stirred for 3 hours to yield pramipexole pamoate as a solid, which was collected, washed, and dried. The solid was characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in
FIG. 13 and Table 7. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 14 . 1H NMR (seeFIG. 21 ) indicates that the molar ratio of Pramipexole to Pamoic acid in this solid is about 1:1. -
TABLE 7 2-Theta d(A) Height Height % 7.659 11.5328 153 24.2 11.817 7.4826 157 24.8 12.130 7.2905 56 8.9 13.843 6.3920 354 56.0 15.303 5.7852 632 100.0 16.796 5.2741 72 11.4 17.285 5.1259 64 10.1 18.020 4.9186 64 10.1 18.903 4.6908 159 25.2 21.141 4.1989 595 94.1 23.082 3.8502 194 30.7 23.680 3.7541 136 21.5 25.542 3.4846 83 13.1 26.421 3.3706 135 21.4 27.904 3.1948 50 7.9 30.109 2.9656 52 8.2 30.682 2.9115 53 8.4 - Preparation of Pramipexole Pamoate at a 1:1 Molar Ratio of Pramipexole to Pamoic Acid from a Mixture of Acetone and Methanol.
- 100 mg of amorphous pramipexole pamoate salt from Example 7 was dissolved in 0.6 mL of methanol at room temperature. To the solution was added 3 mL of acetone with stirring to yield pramipexole pamoate as a crystalline solid, which was collected, washed, and dried. The solid was characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in
FIG. 15 and Table 8. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 16 . 1H NMR indicates that the molar ratio of Pramipexole to Pamoic acid in this solid is about 1:1. -
TABLE 8 2-Theta d(A) Height Height % 7.416 11.9106 85 26.8 11.421 7.7416 87 27.4 11.740 7.5317 100 31.5 12.043 7.3428 235 74.1 13.378 6.6128 83 26.2 14.999 5.9018 317 100.0 16.417 5.3949 69 21.8 17.243 5.1383 115 36.3 17.698 5.0074 71 22.4 18.595 4.7677 72 22.7 19.704 4.5017 93 29.3 20.022 4.4310 79 24.9 20.364 4.3574 239 75.4 20.905 4.2459 188 59.3 22.480 3.9518 151 47.6 23.302 3.8143 149 47.0 23.579 3.7701 65 20.5 24.202 3.6743 68 21.5 25.424 3.5005 123 38.8 25.881 3.4397 47 14.8 27.406 3.2517 59 18.6 29.398 3.0357 50 15.8 31.368 2.8494 37 11.7 33.712 2.6564 34 10.7 34.525 2.5957 34 10.7 - Preparation of Pramipexole Pamoate at a 2:1 Molar Ratio of Pramipexole to Pamoic Acid from a Solution of Ethyl Acetate.
- 50 mg of amorphous pramipexole pamoate salt from Example 7 was dissolved in 2.5 mL of ethyl acetate. The solution was stirred for 5 days at room temperature to yield pramipexole pamoate as a solid, which was collected, washed, and dried. The solid was characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in
FIG. 17 and Table 9. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 18 . 1H NMR (seeFIG. 26 ) indicates that the molar ratio of Pramipexole to Pamoic acid in this solid is about 2:1. -
TABLE 9 2-Theta d(A) Height Height % 6.051 14.5950 100 26.2 9.181 9.6241 81 21.2 10.227 8.6423 100 26.2 10.681 8.2760 261 68.3 11.018 8.0235 112 29.3 12.683 6.9736 225 58.9 13.523 6.5426 382 100.0 14.942 5.9241 277 72.5 16.276 5.4416 166 43.5 17.243 5.1385 101 26.4 18.062 4.9073 183 47.9 18.681 4.7460 207 54.2 19.957 4.4454 138 36.1 20.483 4.3324 143 37.4 21.780 4.0771 95 24.9 22.325 3.9790 212 55.5 22.766 3.9028 134 35.1 23.644 3.7598 66 17.3 24.820 3.5843 73 19.1 25.566 3.4814 106 27.7 27.479 3.2432 56 14.7 28.900 3.0868 68 17.8 - Preparation of Pramipexole Pamoate at a 2:1 Molar Ratio of Pramipexole to Pamoic Acid from a Solution of Tetrahydrofuran
- 50 mg of amorphous pramipexole pamoate salt from Example 7 was dissolved in 2.5 mL of tetrahydrofuran (THF). The solution was stirred for 10 days at room temperature to yield pramipexole pamoate as a solid, which was collected, washed, and dried. The solid was characterized by XRPD and DSC. A typical example of an X-ray diffraction pattern for this solid is shown in
FIG. 19 and Table 10. A typical example of a differential scanning calorimetry thermogram for this solid is shown inFIG. 20 . 1H NMR (seeFIG. 22 ) indicates that the molar ratio of Pramipexole to Pamoic acid in this solid is about 2:1. -
TABLE 10 2-Theta d(A) Height Height % 6.096 14.4874 773 45.0 11.018 8.0238 341 19.9 11.563 7.6469 400 23.3 12.164 7.2701 177 10.3 12.421 7.1200 221 12.9 13.539 6.5348 458 26.7 14.856 5.9582 449 26.2 16.289 5.4373 167 9.7 17.883 4.9559 1717 100.0 18.903 4.6908 558 32.5 19.227 4.6125 141 8.2 19.546 4.5379 313 18.2 20.500 4.3288 175 10.2 21.286 4.1707 617 35.9 21.799 4.0736 425 24.8 22.441 3.9586 428 24.9 23.208 3.8294 683 39.8 23.625 3.7628 291 16.9 24.024 3.7013 529 30.8 24.959 3.5646 197 11.5 26.313 3.3842 152 8.9 26.799 3.3239 132 7.7 27.240 3.2711 192 11.2 27.820 3.2042 130 7.6 28.887 3.0882 109 6.3 29.488 3.0267 67 3.9 30.072 2.9692 54 3.1 30.643 2.9151 196 11.4 31.409 2.8458 114 6.6 32.287 2.7704 49 2.9 34.501 2.5974 151 8.8 35.565 2.5221 59 3.4 35.925 2.4977 61 3.6 36.968 2.4296 89 5.2 38.144 2.3574 112 6.5 38.677 2.3261 47 2.7 - Characterization of Pramipexole Pamoates at a 1:1 or 2:1 Molar Ratio of Pramipexole to Pamoic Acid by Proton Nuclear Magnetic Resonance Spectroscopy (1H-NMR).
- Pramipexole pamoates (1:1 and 2:1) were analyzed using 1H-NMR. The 1H-NMR spectra are provided in
FIGS. 21 and 22 .FIG. 21 is the 1H-NMR spectrum of the 1:1 salt prepared from a mixture of acetone and water (Example 7). The molar ratio of pramiperxol to pamoic acid was approximately 1:1 measured from proton integration of the 1H NMR spectrum. 1H NMR (500 MHz, DMSO-d6) chemical shifts were recorded at (all values in ppm) 8.65 (b, 2H), 8.28 (s, 2H), 8.17 (d, 2H), 7.73 (d, 2H), 7.21 (t, 2H), 7.09 (t, 2H), 6.84 (s, 2H), 4.72 (s, 2H), 3.49 (m, 3H), 2.97 (m, 3H), 2.50-2.68 (m, 6H), 2.17 (m, 1H), 1.83 (m, 1H), 1.65 (m, 2H), 0.94 (t, 3H).FIG. 22 is the 1H-NMR spectrum of the 2:1 salt prepared in a solution of tetrahydrofuran (Example 10). The molar ratio of pramipexole to pamoic acid was approximately 2:1 measured from proton integration of the 1H-NMR spectrum. 1H-NMR (500 MHz, DMSO-d6) chemical shifts were recorded at (in ppm) 8.65 (b, 2H), 8.19 (m, 2H), 7.63 (d, 1H), 7.11 (m, 1H), 6.99 (m, 1H), 6.78 (s, 2H), 4.67 (s, 1H), 3.59 (m, 2H), 3.49 (m, 1H), 2.97 (m, 3H), 2.50-2.68 (m, 3H), 2.17 (m, 1H), 1.51-1.83 (m, 5H), 1.65 (m, 2H), 0.95 (t, 3H). - Crystalline Form Screening of Pramipexole Pamoate Salt Using Different Solvent Systems.
- This example provides a crystalline form screening summary of the pramipexole pamoate salt described in the above examples. The solvent used to prepare the crystalline form of pramipexole pamoate can be important as many solvents or solvent system did not work for the formation of crystalline salt form.
- A panel of solvents or the combination of these solvents including water, alkanols (e.g. methanol and ethanol), alkyl ketones (e.g. acetone), alkanes (e.g. n-heptane), acetonitrile, toluene, DMSO, alkyl ester (e.g. ethyl acetate), halogenated alkanes (e.g. chloroform), THF, and 1,4-dioxane were screened to generate the crystalline form of the pramipexole pamoate salt. Using these solvents, different types of crystallization techniques known by one in the art were used including cooling, evaporation, and addition of a second solvent to reduce the solubility of the solute (technique known as anti-solvent or drown-out).
- When a mixture of acetone and water or a mixture of acetone and methanol was used as solvent system, two different crystalline forms of a mono-pramipexole pamoate salt were obtained using amorphous pramipexole pamoate salt as depicted in Examples 7 and 8. However, as described in Examples 9 and 10, two different crystalline forms of a semi-pramipexole pamoate salt were obtained from amorphous pramipexole pamoate salt when using ethyl acetate or tetrahydrofuran (THF) as solvent system.
- Between two crystalline forms of mono-pramipexole pamoate salt obtained using the above solvent systems, the form that was obtained from acetone and water in Example 7 is more stable. The form from Example 8 started converting into the crystalline form depicted in Example 7 upon standing at room temperature after 7 days. For the two crystalline forms of semi-pramipexole pamoate salt, the form described in Example 10 was more stable. The crystalline form of semi-pramipexole pamoate salt from Example 9 was converting into amorphous state when placed in the dry box at room temperature.
- Preparation of Ropinirole Pamoate at a 2:1 Molar Ratio of Ropinirole to Pamoic Acid from a Mixture of DMSO and Water.
- Ropinirole (1.3 g, 5 mmol) and Pamoic Acid (0.967 g, 2.5 mmol) was added into DMSO (8 mL) with stirring to form a solution. The resultant solution was slowly added to water (250 mL) at room temperature which produced a white solid. The solid was collected on a filter, washed with water, and dried in vacuum at 45° C. to generate Ropinirole Pamoate as white solids (2.1 g, 92.6%).
- A. Preparation of Rotigotine Pamoate at a 1:1 Molar Ratio of Rotigotine to Pamoic Acid from a Mixture of DMSO and Water.
- Rotigotine (3 g, 9.51 mmol) and Pamoic Acid (3.68 g, 9.51 mmol) was added into DMSO (40 mL) with stirring to form a solution. The resultant solution was slowly added to water (500 mL) at room temperature which produced a white solid. The solid was collected on a filter, washed with water, and dried in vacuum at 45° C. to generate Rotigotine Pamoate as white solids (5 g, 74.9%).
- B. Preparation of Rotigotine Pamoate at a 2:1 Molar Ratio of Rotigotine to Pamoic Acid from a Mixture of DMSO and Water.
- Rotigotine (1 g, 3.17 mmol) and Pamoic Acid (0.614 g, 1.585 mmol) was added into DMSO (8 mL) with stirring to form a solution. The resultant solution was slowly added to water (500 mL) at room temperature which produced a white solid. The solid was collected on a filter, washed with water, and dried in vacuum at 45° C. to generate Rotigotine Pamoate as white solids (2 g, 77.4%).
- Preparation of Pramipexole Pamoate at a 1:1 Molar Ratio of Pramipexole to Pamoic Acid from a Mixture of DMSO and Ethyl Acetate (EA).
- Pramipexole (5.0 g, 23.44 mmol) and Pamoic acid (9.08 g, 23.44 mmol) was dissolved by stirring at room temperature in DMSO (50 mL). The solution was then slowly added to ethyl acetate (2 L) at room temperature to generate a white solid. The solid was collected on a filter and dried in vacuum at 45° C. to give pramipexole pamoate at a 1:1 Molar ratio of Pramipexole to Pamoic acid (14.0 g, 99.0%).
- It is to be appreciated that the Detailed Description section, and not the Summary and Abstract sections, is intended to be used to interpret the claims. The Summary and Abstract sections may set forth one or more but not all exemplary embodiments of the present invention as contemplated by the inventor(s), and thus, are not intended to limit the present invention and the appended claims in any way.
- The present invention has been described above with the aid of functional building blocks illustrating the implementation of specified functions and relationships thereof. The boundaries of these functional building blocks have been arbitrarily defined herein for the convenience of the description. Alternate boundaries can be defined so long as the specified functions and relationships thereof are appropriately performed.
- With respect to aspects of the invention described as a genus, all individual species are individually considered separate aspects of the invention. If aspects of the invention are described as “comprising” a feature, embodiments also are contemplated “consisting of or “consisting essentially of” the feature.
- The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art, readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance.
- The breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
- All of the various aspects, embodiments, and options described herein can be combined in any and all variations.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.
Claims (12)
1-65. (canceled)
66. A method of treating Parkinson's disease, comprising administering to a subject in need thereof a pharmaceutical composition comprising a pamoate salt of a monoamine anti-Parkinson's disease agent and a pharmaceutically acceptable carrier.
67. The method of claim 66 , wherein the pharmaceutically acceptable carrier is a viscous aqueous or nonaqueous carrier.
68. The method of claim 66 , wherein the pharmaceutical composition is administered by injection.
69. The method of claim 67 , wherein administering the pharmaceutical composition provides a duration of efficacy of the monoamine for least about 7 days.
70. The method of claim 66 , wherein the pharmaceutical composition comprises a crystalline Form I of pamoate salt of rotigotine, which is characterized by an X-ray Powder diffraction (“XRPD”) spectrum having both peaks at 4.6 and 9.3, ±0.2° 2-theta.
71. The method of claim 66 , wherein the pharmaceutical composition comprises a crystalline form of pamoate salt of ropinirole, wherein the crystalline form is Form A, Form B, Form C, Form D, or Form E, wherein
Form A is characterized by an XRPD spectrum having the following peaks: 4.3, 17.1, 18.6, and 20.5, ±0.2° 2-theta;
Form B is characterized by an XRPD spectrum having the following peaks: 11.5, 16.4, 21.0, 23.1, 23.4, and 26.2, ±0.2° 2-theta;
Form C is characterized by an XRPD spectrum having peaks at 16.1 and 18.8, ±0.2° 2-theta;
Form D is characterized by an XRPD spectrum having the following peaks: 14.3, 17.9, and 25.2, ±0.2° 2-theta; and
Form E is characterized by an XRPD spectrum having the following peaks: 11.7, 12.0, and 21.0, ±0.2° 2-theta.
72. The method of claim 66 , wherein the pharmaceutical composition comprises a crystalline form of pamoate salt of pramipexole, wherein the crystalline form is Form 1, Form 2, Form 3, or Form 4, wherein
Form 1 is characterized by an XRPD spectrum having one or more of the following peaks: 13.8, 15.3, and 21.1, ±0.2° 2-theta;
Form 2 is characterized by an XRPD spectrum having one or more of the following peaks: 12.0, 15.0, 20.4, and 20.9, ±0.2° 2-theta;
Form 3 is characterized by an XRPD spectrum having one or more of the following peaks: 10.7, 12.7, 13.5, and 14.9, ±0.2° 2-theta; and
Form 4 is characterized by an XRPD spectrum having the following peaks: 6.1, and 17.9, ±0.2° 2-theta.
73. The method of claim 72 , wherein the crystalline form is Form 1, wherein the Form 1 is characterized by an XRPD spectrum having the following peaks: 7.7, 11.8, 13.8, 15.3, 18.9, 21.1, 23.1, 23.7, and 26.4, ±0.2° 2-theta.
74. The method of claim 72 , wherein the crystalline form is Form 2, wherein the Form 2 is characterized by an XRPD spectrum having the following peaks: 12.0, 15.0, 20.4, 20.9, 22.5, and 23.3, ±0.2° 2-theta.
75. The method of claim 72 , wherein the crystalline form is Form 3, wherein the Form 3 is characterized by an XRPD spectrum having the following peaks: 10.7, 12.7, 13.5, 14.9, 18.7, and 22.3, ±0.2° 2-theta.
76. The method of claim 72 , wherein the crystalline form is Form 4, wherein the Form 4 is characterized by (a) an XRPD spectrum having the following peaks: 6.1, 17.9, 21.3, and 23.2, ±0.2° 2-theta.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/586,354 US20220296568A1 (en) | 2017-08-17 | 2022-01-27 | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762546984P | 2017-08-17 | 2017-08-17 | |
PCT/US2018/046916 WO2019036624A1 (en) | 2017-08-17 | 2018-08-17 | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
US202016639170A | 2020-02-14 | 2020-02-14 | |
US17/586,354 US20220296568A1 (en) | 2017-08-17 | 2022-01-27 | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/046916 Continuation WO2019036624A1 (en) | 2017-08-17 | 2018-08-17 | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
US16/639,170 Continuation US11234961B2 (en) | 2017-08-17 | 2018-08-17 | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220296568A1 true US20220296568A1 (en) | 2022-09-22 |
Family
ID=65362489
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/639,170 Active 2039-01-08 US11234961B2 (en) | 2017-08-17 | 2018-08-17 | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
US17/586,354 Pending US20220296568A1 (en) | 2017-08-17 | 2022-01-27 | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/639,170 Active 2039-01-08 US11234961B2 (en) | 2017-08-17 | 2018-08-17 | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
Country Status (5)
Country | Link |
---|---|
US (2) | US11234961B2 (en) |
EP (1) | EP3668501A4 (en) |
CN (1) | CN111212640A (en) |
CA (1) | CA3072994A1 (en) |
WO (1) | WO2019036624A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11234961B2 (en) * | 2017-08-17 | 2022-02-01 | Zi-Qiang Gu | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
CN110003195B (en) * | 2019-05-21 | 2020-05-26 | 湖北中医药大学 | Lurasidone crystal, preparation method thereof and application thereof in injection drug delivery system |
WO2021109880A1 (en) * | 2019-12-06 | 2021-06-10 | 上海医药集团股份有限公司 | Pharmaceutical composition, complementary kit and application thereof |
CN111728956B (en) * | 2020-07-06 | 2022-04-19 | 济南大学 | Pramipexole sustained-release microspheres and preparation method thereof |
CN116367833A (en) * | 2020-11-19 | 2023-06-30 | 四川科伦药物研究院有限公司 | Salt of benzothiazole compound, crystal form and application thereof |
CN115260119B (en) * | 2022-07-26 | 2023-02-10 | 山东京卫制药有限公司 | Pramipexole xinafoate and drug sustained release preparation thereof |
CN115073391B (en) * | 2022-07-26 | 2023-04-07 | 山东京卫制药有限公司 | Novel crystal form of pramipexole triphenacetate and preparation method thereof |
CN115141161B (en) * | 2022-07-26 | 2023-03-28 | 山东京卫制药有限公司 | Crystal form A of pramipexole xinafoate and preparation method thereof |
CN115215818B (en) * | 2022-07-26 | 2023-03-17 | 山东京卫制药有限公司 | Pramipexole triphenyl acetate and drug sustained release preparation thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070093495A1 (en) * | 2003-04-11 | 2007-04-26 | Fariello Ruggero | Methods for treatment of parkinson's disease |
US20140377365A1 (en) * | 2013-06-19 | 2014-12-25 | Map Pharmaceuticals, Inc. | Sustained-release formulation of rotigotine |
US9353059B2 (en) * | 2011-11-29 | 2016-05-31 | Zi-Oiang Gu | Donepezil pamoate, method of preparation and use thereof |
US11234961B2 (en) * | 2017-08-17 | 2022-02-01 | Zi-Qiang Gu | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807570A (en) | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
DE10041479A1 (en) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition for the administration of N-0923 |
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
PA8578501A1 (en) * | 2002-07-25 | 2005-02-04 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
US7365086B2 (en) | 2003-07-25 | 2008-04-29 | Synthon Ip Inc. | Pramipexole acid addition salts |
WO2005055983A2 (en) | 2003-12-09 | 2005-06-23 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
BRPI0513846A (en) | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | prolonged-release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method of manufacture thereof and use thereof |
US20110190356A1 (en) | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
EP3653600A1 (en) | 2010-07-23 | 2020-05-20 | Grünenthal GmbH | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
NO2802319T3 (en) * | 2012-01-12 | 2018-03-24 |
-
2018
- 2018-08-17 US US16/639,170 patent/US11234961B2/en active Active
- 2018-08-17 EP EP18845933.3A patent/EP3668501A4/en active Pending
- 2018-08-17 WO PCT/US2018/046916 patent/WO2019036624A1/en unknown
- 2018-08-17 CN CN201880067148.3A patent/CN111212640A/en active Pending
- 2018-08-17 CA CA3072994A patent/CA3072994A1/en active Pending
-
2022
- 2022-01-27 US US17/586,354 patent/US20220296568A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070093495A1 (en) * | 2003-04-11 | 2007-04-26 | Fariello Ruggero | Methods for treatment of parkinson's disease |
US9353059B2 (en) * | 2011-11-29 | 2016-05-31 | Zi-Oiang Gu | Donepezil pamoate, method of preparation and use thereof |
US20140377365A1 (en) * | 2013-06-19 | 2014-12-25 | Map Pharmaceuticals, Inc. | Sustained-release formulation of rotigotine |
US11234961B2 (en) * | 2017-08-17 | 2022-02-01 | Zi-Qiang Gu | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
Non-Patent Citations (2)
Title |
---|
Huot, Parkinson's disease (2015), 2015, 60942 * |
Sohya, PSYCHOGERIATRICS 2017; 17: 502–503 * |
Also Published As
Publication number | Publication date |
---|---|
US11234961B2 (en) | 2022-02-01 |
EP3668501A4 (en) | 2021-03-17 |
WO2019036624A1 (en) | 2019-02-21 |
CN111212640A (en) | 2020-05-29 |
EP3668501A1 (en) | 2020-06-24 |
US20200230103A1 (en) | 2020-07-23 |
CA3072994A1 (en) | 2019-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220296568A1 (en) | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof | |
US10952958B2 (en) | Donezil pamoate, method of preparation and use thereof | |
JP6101742B2 (en) | 1- [2- (2,4-Dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | |
KR101536023B1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
WO2017167180A1 (en) | Vortioxetine pamoic acid salt and crystal form thereof | |
RU2624446C9 (en) | Tricyclic compounds, compositions containing these compounds and their use | |
US20180071230A1 (en) | Formulations, salts and polymorphs of transnorsertraline and uses thereof | |
US20210198236A1 (en) | Crystals of cyclic amine derivative and pharmaceutical use thereof | |
BR112019003201A2 (en) | compound for use in the treatment of neurogenic orthostatic hypotension | |
EP4021406A1 (en) | Compositions for small molecule therapeutic agent compounds | |
KR100859609B1 (en) | Malic Acid Addition Salts of Terbinafine | |
EA042675B1 (en) | GABA-A RECEPTOR LIGAND | |
JP2010235535A (en) | Preventive or therapeutic agent of chorioretinopathy containing ppar alpha agonist as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |